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Despite improvements in preventive, diagnostic, and therapeutic approaches, lung cancer 
remains the leading cause of cancer-related deaths in the U.S. There are currently no effective 
therapies for those diagnosed with later stage lung cancer. Recent efforts have focused on 
targeting specific lung cancer-related growth pathways, such as the hepatocyte growth factor 
(HGF)/c-Met signaling pathway. HGF/c-Met signaling plays a critical role in mediating 
proliferation, angiogenesis, invasion, and inflammatory responses in non-small cell lung cancer 
(NSCLC). This signaling pathway also confers resistance to therapies targeting other growth 
factor pathways such as epidermal growth factor receptor (EGFR) and vascular endothelial 
growth factor (VEGF). This study focuses on two aspects of HGF/c-Met signaling relevant to 
lung cancer: HGF stimulated c-Met angiogenic response and EGFR ligand-induced c-Met pro-
cancer signaling. We previously reported airway expression of a human HGF transgene (HGF 
TG) produced mice that were more susceptible to lung tumorigenesis induced by a tobacco 
carcinogen. Here we show untreated HGF TG mice display enhanced vascularization and lymph 
vessel formation in the lungs compared to wild-type (WT) littermates, as ascertained by 
microvessel density. Whole lung microarray analysis consistently found significant decreases in 
expression of genes involved in angiogenesis including the VEGF family of genes (Vegfa,Vegfb, 
Vegfc, Vegfd/Figf) at 10, 20, and 40 weeks of age in HGF TG animals compared to WT 
littermates. HGF TG lung tumors derived from carcinogen treated HGF TG mice demonstrated 
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reduction in VEGF genes with an increased expression of five Cxcl family genes including Cxcl1 
and Cxcl2 (murine forms of IL-8). Thus, increased vascularization produced by airway over-
expression of HGF may occur through direct activation of c-Met on endothelial cells and 
expression of inflammatory mediators, rather than induction of VEGF pathways. Ligand-
independent delayed and prolonged activation of c-Met has also been demonstrated previously 
by our laboratory via cross-talk from the EGFR pathway. Here we show that prolonged 
activation of STAT3 by EGFR-ligands is dependent on delayed c-Met activation. Inhibition of c-
Met, by PHA665752, eliminates EGFR stimulated activation of STAT3 at delayed time points. 
The failure of Src inhibition, by PP2, to block delayed phospho-STAT3, and the co-
immunoprecipitation of STAT3 with c-Met 8-24hours post EGF stimulation, suggests STAT3 is 
directly activated by c-Met. These data reinforce the idea that delayed c-Met activation is utilized 
by EGFR to potentiate its full biological effects through STAT3. Both ligand-dependent transient 
and ligand-independent delayed c-Met activation appear to be important in lung tumorigenesis. 
The findings of this study support future development of novel HGF/c-Met and EGFR 
combination therapies in NSCLC.  
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1.0  INTRODUCTION 
1.1 LUNG CANCER STATISTICS AND RISK FACTORS 
Lung cancer is the leading cause of cancer related deaths in the United States and worldwide (1). 
Though incidence rates have started to decline (1.9% decrease per year in men, 0.3% in women), 
there is still an estimated 226,160 new cases of lung cancer expected in 2012 (2). Lung cancer 
deaths will account for 28% of all cancer related deaths this year alone. The five-year survival 
rate has remained largely unchanged at only 16% for decades. The rate is 52% when the cancer 
is detected while still localized, but only 15% of cases are diagnosed at this early a stage (2). 
Thus, despite the decreased number of cases each year due to decreasing risk factors such as 
cigarette smoking, new lung cancer cases are often diagnosed at late stages when effective 
therapeutic options are few.  
 Exposure to tobacco by means of cigarette, pipe, or cigar smoke remains the greatest risk 
factor for lung tumorigenesis accounting for 90% of all cases (2).  In 2009, 23.5% of men and 
17.9% of women in the United States smoked, with the greatest prevalence in the 25-44 year old 
age group (24.0%) (3). There are currently over one billion smokers worldwide, with four-fifths 
of those in low or middle-income countries (3). It is estimated that tobacco related deaths will 
increase to 8.3 million by 2030, with 80% of deaths occurring in developing countries (4).   
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Other risk factors include: exposure to radon gas released from soil and building 
materials, exposure to secondhand smoke, asbestos, arsenic, chromates, and generalized air 
pollution (2, 5). Gender differences have been reported to play a role in the development of lung 
tumors. Nearly 80% of lung cancer in the non-smoking population occurs in females (3). The 
observed sex differences may be due to several factors including differences in environmental 
exposures (6) or steroid hormones, such as the estrogen receptor family (7), increasing 
susceptibility to lung cancer development and progression.   
Two basic pathological classifications are used to describe lung cancer: small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for nearly 85% of all 
lung carcinomas, and generally grows more slowly than SCLC (1). NSCLC can be further 
divided by histology into subtypes including adenocarcinoma (35%), large cell carcinoma 
(<10%), and squamous cell carcinoma (25%). Tumors that are classified by cytological 
appearance provide oncologists with characteristics that allow for more effective treatment.    
1.2 DIAGNOSIS AND THERAPIES 
Lung cancer is often undiagnosed until late stages of the disease (IIIB, IV). This can be attributed 
partially to the fact that early stages of the disease tend to be asymptomatic. There are also no 
formal guidelines in place for early screening. The National Lung Screening Trial recently 
compared two methods of detecting lung cancer: low-dose helical computed tomography (CT) 
and standard chest X-ray. Results from this study revealed that patients who received CT scans 
had a lower mortality rate than those who received standard chest X-rays (8). However, potential 
risks associated with radiation exposure from multiple CT scans have not been evaluated. 
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 Treatments, based on type and stage of cancer, include radiation therapy, surgery, 
chemotherapy, and targeted therapies (2). The treatment choice for early-stage lung cancer, 
surgical resection, focuses on removing as much of the tumor as possible without damaging 
adjacent tissue. Chemotherapy treatment destroys rapidly proliferating cells, and thus is the usual 
treatment choice for SCLC. Chemotherapy and/or radiotherapy for late-stage NSCLC offer only 
short-term survival benefits (9). Recent research has demonstrated a potential for targeted drugs 
in advanced-stage NSCLC patients especially when combined with chemotherapy treatments.   
1.3 GROWTH FACTOR SIGNAING IN LUNG CANCER 
Escape from normal control pathways is a key event in the development of lung cancer. 
Following the discovery of epidermal growth factor (EGF), a multitude of secreted factors that 
control key pathways such as cell proliferation, survival, and metastasis have been identified 
(10). These pathways are often deregulated in malignancies (11). Growth factors act through 
autocrine and paracrine mechanisms but cannot cross the cell membrane. Instead, they often bind 
cell surface receptors that possess intrinsic tyrosine kinase activity. Abnormalities, by means of 
mutation or expression deregulation, have been reported in many cancers, including NSCLC 
(12). Thus, these molecules may serve as valuable targets for therapy. Current FDA approved 
targeted therapy in NSCLC is limited to inhibition of the EGFR and vascular endothelial growth 
factor (VEGF) pathways. 
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1.3.1 Mediators of Angiogenesis 
Several growth factors mediate angiogenesis, the formation of new blood vessels from pre-
existing vasculature, which plays a crucial role in the development and continuation of tumor 
progression. Microvessel density is often utilized to quantify angiogenic activity (13, 14). 
Several studies have demonstrated an association between increased microvessel density and 
poor patient outcomes in NSCLC (14-16). The inhibition of angiogenesis is expected to prevent 
growth and emergence of tumor progression (17). So far, bevacizumab is the only approved anti-
angiogenic agent for NSCLC. The combination of bevacizumab with carboplatin/paclitaxel was 
approved for first-line treatment of patients with NSCLC in 2006 (18).  
Bevacizumab is a humanized monoclonal antibody that binds and inhibits all members of 
the VEGF family. VEGF is largely considered the key regulator in the promotion of endothelial 
cell proliferation and vascular permeability (12). Early studies indentified VEGF as a significant 
prognostic factor in NSCLC (18). Reports of resistance to these anti-VEGF treatments have been 
reported in several types of cancer, including NSCLC (17, 19). Recent evidence suggests other 
pathways such as interleukins, platelet-derived growth factor (PDGF), fibroblast growth factor 
(FGF), and hepatocyte growth factor (HGF) are sufficient for signaling that promotes 
angiogenesis (20). Levels of HGF and other pro-angiogenic cytokines have been reported to be 
elevated before progression in colorectal cancer patients being treated with bevacizumab (21).  
Tobacco smoke, an important risk factor for lung carcinoma, is an irritant that induces the 
release of pro-inflammatory cytokines, chemokines and reactive oxygen species (22). Several 
genes associated with the promotion of inflammation have also been shown to play important 
roles in the promotion of angiogenesis (e.g. KRAS, TNFα, Interleukins) (23). Interleukin 6 (IL-
6) and interleukin 8 (IL-8) are CXC chemokines that act as chemoattractants for neutrophils and 
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macrophages, as well as stimulate proliferation of endothelial and lung tumor cells (24). The 
CXC family of chemokines are heparin-binding molecules that contain four conserved cysteine 
residues (25). These chemokines are subdivided into ELR+ and ELR- depending on the presence 
(+) or absence (-) of a Glu-Leu-Arg tripeptide motif immediately preceding the first cysteine on 
the NH3 terminus (Table 1). ELR+ CXC chemokines are angiogenic, whereas ELR- CXC 
chemokines are angiostatic (24, 26). CXC receptor type 2, which mediates angiogenic effects, is 
located on neutrophils, endothelial cells, and tumor cells (27-29). A recent study in CXCR2 
deficient mice demonstrated its signaling is required for tumor growth and angiogenesis 
regardless of the presence of VEGF (30). Similarly, inhibition of IL-8 via a neutralizing antibody 
reduced tumorigenesis of NSCLC in SCID mice (31). Other studies have also determined CXC 
chemokines are important for the promotion of angiogenesis in patients with NSCLC (32, 33) 
and have reported IL-8 as a proliferative factor for NSCLC cells (34-36).  
 
Table 1. Angiogenic chemokine ligands and receptors (Strieter, RM, et al. 2008). 
 
Systematic Nomenclature Old Nomenclature Receptor 
Angiogenic/arteriogenic   
    CXCL1 Gro-α CXCR2 
    CXCL2 Gro-β CXCR2 
    CXCL3 Gro-γ CXCR2 
    CXCL5 ENA-78 CXCR2 
    CXCL6 GCP-2 CXCR2 
    CXCL7 NAP-2 CXCR2 
    CXCL8 IL-8 CXCR2 
    CCL2 MCP-1 CCR2 
    CCL11 Eotaxin CCR3 
    CCL16 HCC-4/LEC CCR1 
Angiostatic   
    CXCL4, CXCL4L1 PF-4, PF-4var CXCR3B* 
    CXCL9 Mig CXCR3B 
    CXCL10 IP-10 CXCR3B 
    CXCL11 I-TAC CXCR3B 
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Growth factors other than VEGF, such as HGF, have been reported to stimulate induction 
and release of these ELR+ CXC chemokines (37). HGF, which will be discussed in greater detail 
later, activates integrins on endothelial cells to trigger development of the lymphatic vessels (22), 
and triggers macrophages to release cytokines such as IL-8 (24). HGF has also been shown to 
directly promote blood vessel formation during tissue repair that does not require VEGFs (38). 
Recently, it has been documented that HGF/c-Met activation also plays a role in resistance to 
sunitinib treatment, a VEGFR and PDGFR inhibitor (19).   
Epidermal growth factor is yet another growth factor pathway known to play a role in the 
regulation of angiogenesis (18). Dual inhibition of VEGFR and EGFR by vandetanib has been 
shown to demonstrate anti-tumor activity. Yet, significant survival benefits were not 
demonstrated in Phase III clinical trials for NSCLC patients (39). 
 
1.3.2 Epidermal Growth Factor Receptor 
Thus far, the most promising inhibition of NSCLC via growth factor blockade has come from 
obstruction of the EGFR signaling pathway. The EGFR family has been studied as a target for 
anticancer therapies in NSCLC for over a decade since the first EGFR-mutant lung cancers were 
described (40, 41). While normal epithelial cells express EGFR, it is over-expressed in up to 
60% of NSCLC tumors (42). When activated via interaction with its ligands EGF, transforming 
growth factor-alpha (TGFα), and amphiregulin (AR), EGFR can form homodimers or 
heterodimers with the other monomers of the EGFR family HER2, HER3, or HER4 (43, 44). 
Dimerization is crucial for trans-autophosphorylation within the intracellular tyrosine kinase 
domain. This is followed by subsequent downstream phosphorylation of the carboxy-terminal 
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tail. These phosphorylated residues serve as the site for interaction with adaptor proteins. The 
adapter proteins in turn modify effector molecules such as RAS/mitogen-activated protein kinase 
(MAPK), phosphatidylinositol 3-kinase (PI3K)/Akt, and signal transducer and activator of 
transcription (STAT) proteins, which promote cell proliferation, motility, and invasion (45).   
In order to block EGFR hyper-activation in NSCLC, tyrosine kinase inhibitors (TKIs) 
and monoclonal antibodies were designed. Cetuximab (brand name: Erbitux), a chimeric 
monoclonal antibody, and panitumumab (brand name: Vectibix), a human monoclonal antibody, 
bind to the extracellular domain of EGFR preventing natural ligand-induced phosphorylation and 
subsequent intracellular signaling. Phase III trials have shown conflicting results using 
cetuximab in chemotherapy-naïve patients regarding overall survival (46). However, when 
combined with chemotherapy clinical outcomes were improved (46, 47). Additional data is 
required before these antibodies can be approved for treatment of NSCLC.  
In 2003 and 2004 the first EGFR TKIs, gefitinib (brand name: Iressa) and erlotinib 
(brand name: Tarceva) were approved for the treatment of advanced NSCLC. Both are orally 
available quinazoline-based molecules that reversibly compete with ATP to inhibit kinase 
activity (48). Both drugs seemed promising in cell and animal models, but had decreased clinical 
efficacy due to resistance. It was determined that patients harboring EGFR mutations benefited 
from EGFR TKIs compared to those with wild-type EGFR. EGFR mutations occur in only 26% 
of NSCLC tumors. This incidence increases to 77% among EGFR TKIs responders (46).    
Despite positive responses to EGFR TKIs, most patients develop resistance within a year 
(46). Resistance can be acquired or intrinsic. Intrinsic resistance is important in NSCLC patients 
expressing wild-type EGFR, which account for the majority of NSCLC cases (49). Secondary 
mutations in EGFR can confer resistance to TKIs. The T790M mutation is found in 50% of 
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patients that relapse after initial response to EGFR TKIs (48). This mutation is thought to block 
EGFR TKI binding but still allow binding of ATP. Other genomic alterations can induce primary 
resistance to EGFR inhibitors, such as activating mutations in downstream signaling transducers. 
KRAS mutations, predominately in codons 12 and 13, occur in 15-20% of lung cancer patients 
and are correlated with poor prognosis (50). These activating mutations occur in molecules 
downstream of receptor activation, thus continuing to drive tumor formation regardless of 
receptor status (49). Divergence to other signal transduction pathways may also confer resistance 
to EGFR inhibition. Redundancy among receptor tyrosine kinases (RTKs) allows for the 
activation of overlapping signaling cascades to continually stimulate effector molecules involved 
in tumor progression. One such pathway, HGF/c-Met, has been demonstrated to be important for 
EGFR resistance in NSCLC. The amplification of c-Met allows for continued activation of 
mediators such as PI3K and MAPK in the presence of EGFR inhibitors (46, 51). Amplified c-
Met combined with the T790M mutation accounts for 70% of acquired EGFR TKI resistance in 
NSCLC (46). Thus, there is a strong basis for exploring the c-Met signaling pathway as a 
therapeutic target in NSCLC.    
1.4 HEPATOCYTE GROWTH FACTOR AND C-MET 
1.4.1 HGF and c-Met Structure 
The MET proto-oncogene encodes a transmembrane receptor with tyrosine kinase activity.  The 
150kDa precursor is glycosylated to become a fully mature 170kDa pro form of c-Met. This pro-
molecule is then cleaved into two subunits, the α-chain (45kDa) and β-chain (150kDa). The 
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mature c-Met receptor is comprised of the two chains connected by a disulfide linkage. The β-
chain forms the transmembrane portion of c-Met. Its intracellular segment contains the 
juxtamembrane and tyrosine kinase domains (Figure 1) (52). The extracellular section forms a 
binding pocket with the solely extracellular α-chain. It is here that the c-Met ligand, HGF, binds. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of c-Met and important phosphorylation sites (Ma, PC, et al. 2003). 
 
Cells of a mesenchymal origin, such as fibroblasts, secrete HGF. HGF was originally 
discovered as a platelet-derived mitogen for hepatocyte cells that induced epithelial cell 
scattering (53). It is secreted as an inactive pro-molecule, which is then activated via cleavage by 
serine proteases (Figure 2) (54). The mature form is composed of an α-chain and β-chain linked 
by a disulfide bridge. Functional HGF binds the c-Met receptor to initiate downstream signaling 
cascades.  
 10 
 
 
 
Figure 2. Structure of pro- and mature HGF (Matsumoto, K, et al. 2001). 
 
 
1.4.2 HGF/c-Met Signaling 
In the canonical pathway, binding of HGF facilitates the dimerization and 
autophosphorylation of key tyrosines in the β-chain of the c-Met receptor. Tyrosine residues 
Y1230, Y1234, and Y1235 are essential to the tyrosine kinase activity of c-Met. Phosphorylation 
at these sites leads to subsequent phosphorylation on tyrosine residues Y1349 and Y1356 (52). 
These form the multi-substrate docking site (MSDS), which is recognized by the majority of 
adaptor molecules that regulate downstream signaling such as c-Src, PI3K, Grb2, or GRB2-
associated-binding protein 1 (Gab1) (Figure 2 and 3) (55). Protein-interactions occur through 
PTB, SH2, and met binding domains (MBD). Phosphorylation at residue Y1003 is recognized by 
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the E3 ubquitin ligase c-Cbl, which then plays a role in the ubiquitinization, internalization, and 
degradation of c-Met (Figure 2) (56).  
HGF/c-Met activates several downstream signaling cascades, which modulate growth, 
motility, anti-apoptosis, inflammation, invasion, and angiogenesis (Figure 3). The Ras/MAPK 
cascade activates cell proliferation and growth (57). This pathway is stimulated in a rapid and 
transient manner. The STAT family of transcription factors, including STAT3, plays a key role 
in invasive phenotypes seen after HGF stimulation (58). HGF is also able to promote 
inflammation or angiogenesis by acting on macrophages or epithelial cells directly through c-
Met receptors (59). Indirectly, HGF promotes angiogenesis and inflammation by stimulating the 
production of cytokines and chemokines including COX-2 (11), or IL-8 (37). 
 
 
 
Figure 3. Canonical HGF/c-Met signal transduction pathway (Matsumoto, K, et al. 2001). 
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1.4.3 Function in Normal Tissues versus Cancer 
In normal tissue, HGF/c-Met signaling is essential for embryonic development and tissue 
regeneration. This pathway is important for placenta and liver development during 
embryogenesis (60). HGF and c-Met knockout mice are both embryonically lethal (61). In adults 
signaling is transient and activated only during injury and repair processes (62). Following injury 
to heart, kidney, or liver, HGF plasma levels increase as secreted HGF from local and/or distant 
sites promote cell migration for the reconstitution of injured tissues (63-65). HGF levels decrease 
to basal conditions once regeneration is complete.  
In cancer cells, this transient signaling is uncontrolled and up-regulated. Tumor stromal 
cells are the main source of HGF in NSCLC. HGF released from stromal cells acts in a paracrine 
mechanism on surrounding epithelial and endothelial cells (66). Over-expression of HGF and c-
Met is present in approximately 50% of lung adenocarcinomas (67-69), and is strongly correlated 
with poor prognosis of NSCLC patients (70-72). An increased number of receptors can drive 
oligomerization of c-Met resulting in ligand-independent activation (73). In addition, mutations 
have been reported that cause the loss of Y1003, the residue involved in regulating 
internalization (74). This loss confers prolonged activation of the c-Met signaling cascade. 
Transient signaling in normal tissues makes HGF and c-Met ideal for targeting tumor cells. 
1.4.4 C-Met Crosstalk and Delayed Activation 
Although typical activation of c-Met occurs by HGF stimulation, c-Met may also be 
activated by ligand-independent means. Cell surface proteins that respond to extracellular signals 
have been shown to activate c-Met through crosstalk or lateral signaling. Proteins that act as c-
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Met partners include integrins, CD44, class B plexins, G protein coupled receptors (GPCRs) and 
other RTKs such as RON and EGFR (75). The mechanism in which these molecules activate c-
Met varies greatly. For example, integrin clustering triggers c-Met phosphorylation independent 
of HGF following cellular adhesion in mouse melanoma cells (76). While these associations are 
likely indirect, HGF-induced interaction of c-Met with the laminin receptor, α6β4, enhances 
phosphorylation of integrin β4 (75). Single-pass transmembrane plexins modulate cytoskeletal 
remodeling and integrin-dependent adhesion. Class B plexins share homology with c-Met in 
their extracellular domains, which allows for ligand-independent association. Activated c-Met 
has been associated with activated plexin B1 in carcinoma cells (77). Another transmembrane 
protein, CD44, can act as a co-receptor for c-Met, thus enhancing HGF-stimulated c-Met 
signaling (75). GPCR ligands such as lysophosphatidic acid (LPA), thrombin, and bradykinin are 
able to induce c-Met phosphorylation via ectodomain shedding (78). Here, loss of the 
extracellular fragment of c-Met allows for the intracellular portions to dimerize in the absence of 
ligand. Moreover, crosstalk may occur between c-Met and other RTKs, EGFR being the most 
well documented of these interactions.   
EGFR and c-Met receptors are often co-expressed in tumors, including NSCLC. 
Activation of c-Met following stimulation with EGFR ligands has been observed in lung and 
epidermal carcinoma cells (79). Crosstalk from EGFR to c-Met occurs in the presence of mutant 
or wild-type EGFR, and correlates with receptor expression levels (75). Our laboratory 
previously demonstrated that invasion of NSCLC cell lines stimulated by prostaglandin E2 
(PGE2) involves EGFR ligand production, which in turn leads to activation of EGFR and 
successive phosphorylation of c-Met (11). We further established that EGFR activation of c-Met 
in NSCLC cells is a delayed event that occurs through an intracellular signaling cascade 
 14 
independently of HGF (80). Delayed lateral signaling from EGFR to c-Met is required to obtain 
the maximal invasive phenotypic response to EGFR ligand stimulation in NSCLC cells (80). 
1.4.5 HGF/c-Met Pathway Therapeutics 
HGF/c-Met inhibition by small molecule inhibitors, and antibodies targeted to HGF or c-Met has 
been shown to reduce tumorigenesis (53, 81, 82). These findings along with the knowledge that 
HGF/c-Met signaling confers resistance to EGFR TKIs, has spurred the development of 
therapeutic agents targeting the HGF/c-Met signal transduction pathway. HGF inhibitor and Met 
antagonist therapeutics function outside target cells. Monoclonal antibodies directed against 
HGF (AMG102), or the c-Met receptor (METMab), disrupt interactions between HGF and c-Met 
at the binding pocket (83). Biological antagonists, NK1, NK2, and NK4 are non-cleavable forms 
of HGF that bind Met without inducing receptor activation (84). While these therapies are 
currently under investigation, the majority of HGF/c-Met inhibitors are c-Met directed TKIs that 
function inside the cell (83, 84).  
In the inactive conformation, an activation loop blocks ATP access to the c-Met catalytic 
domain. Upon activation, the loop is extruded and ATP binds a pocket between the N and C 
lobes (83). The c-Met kinase inhibitors fall under three groups depending on their mode of 
binding. Types I, II, and III are all ATP competitive inhibitors. Type I inhibitors, such as 
PHA665752 and PF02341066, display preferential binding to inactive c-Met proteins (83). Type 
II (BMS-777607) and Type III inhibitors also bind the ATP pocket but extend into other cavities 
of the receptor (83). The efficacies for these inhibitors are currently being evaluated with the 
majority in phase I or II clinical trials. The Met and ALK inhibitor, PF2341066, has shown high 
efficacy in patients with NSCLC containing activating ALK gene fusions or Met alterations (85). 
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A phase III clinical trial is ongoing for this compound with hopes that it will be used in lung 
tumors with the activating ALK fusion gene or c-Met amplification. While initial results from 
clinical studies have shown therapeutic benefits, larger and more rigorous trials will clarify the 
true value and long-term safety of these inhibitors in cancer patients.  
1.4.6 HGF Transgenic Mouse 
In order to effectively study HGF/c-Met signaling in lung tumorigenesis, our laboratory has 
generated and published the phenotype of a transgenic mouse over-expressing human HGF in the 
airways under the control of the Clara cell secretory protein (CCSP) promoter (86). This mouse 
expresses human HGF protein in CCSP-positive cells only and contains a 3.5-fold increased 
level of HGF in the BAL fluid. The transgenic animals do not spontaneously develop lung 
tumors. However, after exposure to the tobacco carcinogen 4-(methylnitrosoamino)-1-(3-
pyridyl)-1-butanone (NNK), HGF TG mice exhibited a significant increase in tumor multiplicity 
compared to wild-type (WT) littermates (86). This effect of HGF over-expression was 
successfully blocked by 90% when using an HGF neutralizing antibody (82). NNK-induced 
tumors in HGF TG and WT littermates had an identical frequency of K-ras mutation of 40%, 
suggesting HGF promotes tumor development regardless of K-ras status. In the presence of HGF 
neutralizing antibody, tumors were more likely to be K-ras mutant when compared to a control 
neutralizing antibody (82); thus suggesting tumors containing mutant K-ras better survive the 
blockade of HGF/c-Met signaling. HGF TG mice were also observed to contain higher 
pulmonary blood vessel production after NNK exposure than their WT littermates. Few studies 
have been completed that further characterize vessel formation and gene expression changes in 
the presence of HGF over-expression.    
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1.5 FOCUS OF RESEARCH 
The research undertaken for the Master’s Degree focused on two aspects of HGF/c-Met 
signaling that are relevant to lung cancer.  
1) Determine which genes are involved in the angiogenic response to HGF.  
2) Understand how HGF-independent activation of c-Met downstream of EGFR   
     contributes to pro-cancer signaling. 
EGFR has been well established to play an important role in lung tumorigenesis. However, a 
lack of clinical efficacy, with c-Met signaling noted as a major factor of acquired resistance, has 
prompted us to explore unanswered questions about HGF/c-Met signaling in lung cancer. Upon 
further investigation, we will gain a better understanding of the critical intermediates involved in 
two differing c-Met signaling cascades; HGF-stimulated blood vessel formation, and EGFR 
ligand-induced c-Met invasion. This knowledge can be utilized for the clinical development of 
novel HGF/c-Met and EGFR combination therapies in NSCLC. 
1.6 MATERIALS AND METHODS 
1.6.1 Chemical Reagents 
PHA665752 was obtained from Pfizer under an approved material transfer agreement (New 
York, NY). PP2 was purchased from Calbiochem (San Diego, CA). Gefitinib and Vandetanib 
were purchased from ChemieTek (Indianapolis, IN). EGF was purchased from Invitrogen 
(Carlsbad, CA). HGF was purchased from R&D Systems (Minneapolis, MN). The c-Met and 
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non-targeting siRNA ON-TARGETplus SMARTpools were purchased from Dharmacon 
(Lafayette, CO).  
1.6.2 Cell Lines and Culture Conditions 
H1435 NSCLC cell line was obtained from American Type Culture Collection (Manassas, VA). 
The 201T cell line was established in our laboratory from a primary lung adenocarcinoma (87). 
Cells were grown in Basal Medium Eagle (BME) or RPMI 1640 containing 10% fetal bovine 
serum and 2mM L-Glutamine. All cells were maintained at 37ºC in 5% CO2. Cells were grown 
to 60-80% confluence in full serum medium and serum-deprived 48 hours prior to growth factor 
stimulation unless otherwise stated. DNA fingerprinting was used to verify the identity of each 
cell line.  
1.6.3 Protein Analysis 
Cellular Isolation and Cytosolic-Nuclear fractionation 
Following experimental treatment, cells were washed twice with 1X phosphate-buffered saline 
(PBS) and lysed with NP-40 lysis buffer (50mM Tris-HCl, 150mM NaCl, 1% NP-40, pH 8.0) 
containing protease inhibitor cocktail (Roche, Indianapolis, IN) and phosphatase inhibitors: 
sodium fluoride (NaF, 25mM) and sodium orthovanadate (NaV, 1.5mM). After being briefly 
sonicated and incubated on ice for 30 minutes, the insoluble fraction was cleared by 
centrifugation at 10,000 x g for 20 min at 4ºC. To analyze subcellular localization of 
STAT3/pSTAT3, nuclear and cytoplasmic protein fractions were collected using Chemicon’s 
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Nuclear Extraction Kit (Millipore, Billerica, MA), following manufacturer’s instructions. The 
BCA-200 Protein Assay Kit (Pierce, Rockford, IL) was utilized for protein quantification.  
 
Tissue Isolation 
For extraction from tissue specimens, tissue sections were immediately frozen in liquid nitrogen 
upon removal. Lung samples were homogenized using a polytron (VWR VIDI 25) in 0.5mL ice-
cold radioimmunoprecipitation assay (RIPA) buffer containing complete mini protease inhibitor 
cocktail tablet. Phenylmethylsulfonyl fluoride stock (0.2M) was added to each lysate and 
incubated on ice for 30 minutes. The insoluble fraction was cleared by centrifugation at 10,000 x 
g for 15 minutes at 4ºC. Protein was quantified using the BCA-200 Protein Assay Kit. 
 
Immunoprecipitation 
Equal amounts of protein were subjected to immunoprecipitation with indicated antibodies while 
rotating overnight at 4ºC. Lysates were then incubated with Protein A-Agarose Beads (Thermo 
Fisher Scientific, Rockford, IL) for 2 hours at 4ºC. Samples were washed 4X with NP-40 lysis 
buffer, followed by resuspension in 2X Laemmli sample buffer (2% SDS, 25% Glycerol, 
62.5mM Tris-HCl pH 6.8, 0.01% Bromophenol Blue, 5% ß-mercaptoethanol). 
 
Western Blotting 
Equal amounts of protein (50µg) were separated on 7.5% or 10% SDS-Tricine gels under 
reducing conditions. Protein was transferred to nitrocellulose membrane before blocking with 
5% milk or BSA, 1x Tris-Buffered Saline (TBS) with Tween 20. Membranes were incubated 
with primary antibodies in 3% milk or BSA, 1x TBST at 4ºC overnight. After primary antibody 
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incubation, blots were washed 3X with 1x TBST (10 minutes each at room temperature), and 
horseradish peroxidase-conjugated anti-mouse, anti-rabbit, or anti-goat IgG was added at a 
1:2,000 dilution for 2 hours at room temperature. After washing another 3X with 1x TBST, 
immunoreactive peptides were visualized using SuperSignal West Pico Chemoluminescent 
substrate (Pierce) followed by exposure to autoradiography film. For re-probing, blots were 
stripped with Restore Western Blot (Thermo Fisher Scientific). Immunoreactive bands were 
quantified by densitometry and ImageQuant analysis. 
 
Primary Antibodies  
Primary Antibody Species; Dilution Manufacturer 
Total c-Met (C-28) Rabbit; 1:1000 (WB) 
1:75 (IHC) 
Santa Cruz Biotechnology (Santa Cruz, 
CA) 
Phospho-c-Met (Y1234/35) Rabbit; 1:1000 Cell Signaling (Beverly, MA) 
Total c-Src Mouse; 1:1000 Invitrogen 
Phospho-STAT3 (Y705) Rabbit; 1:1000 Cell Signaling 
Total STAT3 Rabbit; 1:1000 Cell Signaling 
Phospho-tyrosine (pY99) Mouse; 1:750 Santa Cruz Biotechnology 
β-Actin Mouse; 1:5000 Sigma-Aldrich 
Akt (C-20) Rabbit; 1:1000 Santa Cruz Biotechnology 
Vegfa (A-20) Rabbit; 1:500 Santa Cruz Biotechnology 
Vegfd (C-18) Goat; 1:1000 Santa Cruz Biotechnology 
PARP 1/2 (H-250) Rabbit; 1:1000 Santa Cruz Biotechnology 
LYVE-1 Rabbit; 1:100 Abcam (Cambridge, MA) 
SMA (1A4) Mouse; 1:50 R&D Systems 
PECAM-1 (M-20) Goat; 1:100 Santa Cruz Biotechnology 
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1.6.4 RNA Analysis 
RNA Isolation 
After experimental treatment, cells were washed on ice 2X with 1x PBS. Total RNA was 
extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA) following the manufacturer’s 
protocol. Briefly, cells were lysed with Buffer RLT, subjected to column purification, and 
resuspended in RNase free water. Tissue samples for gene expression analysis were stored in 
RNAlater (Qiagen) at -80ºC. Sections were weighed and homogenized in TRIzol (Invitrogen) 
followed by column purification via the Array Grade Total RNA Isolation Kit (SABiosciences, 
Frederick, MD) according to manufacturer’s instructions. RNA was quantified using a Nanodrop 
2000 spectrophotometer. 
 
Reverse Transcription Polymerase Chain Reaction (RT-PCR)  
Knockdown of c-Met by siRNA transfection was validated using RT-PCR. cDNA was 
synthesized and subjected to PCR using Qiagen’s OneStep RT-PCR Kit. Each 50µl reaction 
contained 500ng total RNA, 12.5mM MgCl2, 0.6µM of c-Met primers: forward (5’-
CAACAGCACTGTTATTACTACTTGGG-3’), reverse (5’-GCACTTGTCGGCATGAACCG-
3’). RT-PCR was completed in an automatic thermocycler under the following conditions: 30 
minutes of reverse transcription at 50ºC, 15 minutes at 95ºC for Taq activation and denaturation, 
25 cycles of 30 seconds denaturation at 94ºC, 30 seconds annealing at 58ºC, and 60 seconds 
extension at 72ºC, followed by 10 minutes at 72ºC for final extension. Twenty microliters of 
each reaction were run on a 1.5% agarose gel. Bands were quantified by densitometry.     
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Microarray Analysis 
Total RNA extracted from whole lung or isolated tumors from HGF TG or WT mice was 
subjected to qPCR analysis (Angiogenesis PCR Array [PAMM-024], SABiosciences) or 
hybridization to Oligo GEArray Mouse Angiogenesis or Cancer Pathway Finder Microarrays 
(SuperArray OMM-44 and OMM-33, respectively). In both cases, cDNA was reverse transcribed 
from total RNA using RT2 First Strand Kit (SABiosciences). cDNA was directly applied to the 
Angiogenesis PCR Array and qPCR was performed on ABI Prism 7700 Sequence Detector 
(Applied Biosystems, Foster City, CA). The threshold cycle (Ct) value of each gene was 
measured and expression analysis was completed using the RT2 Profiler PCR Array Data 
Analysis (www.sabiosciences.com). Prior to overnight hybridization to the Oligo GEArrays, 
cDNA was labeled with biotin-16 using the True-Labeling-AMP Linear RNA Amplication Kit 
(SABiosciences). Signal was detected via exposure to autoradiography film. Data analysis was 
performed using GEArray Expression Analysis Suite (www.sabiosciences.com). Data are 
presented as the relative induction of each gene normalized to housekeeping genes, and are 
representative of two to four independent experiments. These data have been deposited in the 
National Center for Biotechnology Information’s Gene Expression Omnibus (GEO) and are 
accessible through GEO Series accession number GSE20468.   
1.6.5 Mouse Models 
For all experiments mice were either WT (murine HGF) or human HGF transgenic (FVB/N 
strain). Construction of the human HGF transgene, as well as generation and identification of 
HGF TG mice, was previously described (86).  
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Microarray Analysis 
Whole lungs were dissected from untreated WT and HGF TG animals after sacrifice at 10, 20, or 
40 weeks of age. To induce lung tumors, mice were given a total of four intraperitoneal 
injections of 3mg NNK (15mg/mL) over 2 weeks. NNK induced lung tumors were dissected 
from the animals at 20 or 40 weeks of age.  
 
Growth Factor Inhibitors 
WT and HGF TG mice (5 weeks of age) were treated with gefitinib (75mg/kg), vandetanib 
(25mg/kg), or vehicle control (1% Tween-80/0.9% saline). Treatment was administered by oral 
gavage (0.2mL/mouse) twice a week for five weeks. At the end of treatment, animals were 
sacrificed and lungs were inflated with 10% buffered formalin under 25cm intra-alveolar 
pressure and removed. Half of the lung was harvested for protein and RNA analysis; the other 
half was fixed in 10% formalin for immunohistochemical (IHC) analysis. Animal care was in 
strict compliance with the institutional guidelines.    
1.6.6 Immunohistochemistry 
Whole mouse lungs were fixed in 10% buffered formalin and stored in 100% ethanol. Tissues 
were then embedded in paraffin, sectioned, and mounted on slides. Slides were deparaffinized, 
rehydrated, and steamed in EDTA (pH 8.0) followed by 3% hydrogen peroxide at room 
temperature for antigen retrieval. To identify vessel expression of the c-Met receptor, slides were 
stained with anti-c-Met (C-28) for 1 hour. Antibody against PECAM-1 (M20, 1.5 hours) was 
used as a pan-endothelial marker. Staining of lymphatic vessels was accomplished with anti-
LYVE-1 for 1 hour. H&E staining was also performed on serial sections from the same lung 
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specimens. Microvessels, as detected by PECAM-1, were counted in five WT mice per time 
point. Lymphatic vessels, as detected by LYVE-1, were counted in ten high-magnification areas 
per lung from six HGF TG and six WT mice at 20 weeks of age. Results are expressed as the 
mean number of blood vessels per area ± standard error. 
1.6.7 Immunofluorescence 
Dual immunofluorescence was utilized to distinguish the maturity of blood vessels. Whole lung 
samples were fixed in 10% formalin and stored in 100% ethanol. Tissues were embedded in 
paraffin, sliced, and mounted on slides. Slides were deparaffinized with xylenes, rehydrated, and 
subjected to antigen retrieval via heating in citrate buffer (pH 6.0) for ten minutes. After 
blocking with 10% normal serum in PBS with 2% BSA, slides were incubated overnight at 4ºC 
with a mixture of anti-PECAM (M20) and anti-smooth muscle actin (SMA) in PBS with 0.5% 
BSA. Slides were washed 3X with PBS-Tween 20 (PBST) five minutes each time. Secondary 
antibody incubation was performed in the dark with donkey anti-goat-546 and donkey anti-
mouse-488 Alexa-fluorophore conjugated IgG (Invitrogen) at a dilution of 1:500 in 0.5% BSA 
for 1 hour at room temperature. Slides were washed another 3X with PBS and mounted with 
Vectasheild Fluorescence Mounting Medium (Vector Laboratories, Burlingame, CA). Vessels as 
detected by PECAM or SMA were counted in seven high-magnification areas per lung from six 
HGF TG and six WT mice at 20 weeks of age. Results are presented as the mean number of 
mature vessels per area (as stained by SMA), total blood vessels per area (as stained by 
PECAM), and percentage of SMA-positive vessels (SMA stained vessels/total vessels stained by 
PECAM) ± standard error. 
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1.6.8 siRNA Transfection 
201T cells were transfected with 50pmol of either non-targeting or c-Met siRNA pools using 
Oligofectamine (Invitrogen) in serum free medium. After 8 hours, transfection medium was 
replaced with serum containing medium overnight followed by serum starvation and 
experimental treatment.  
1.6.9 Statistical Analyses 
All values were obtained using Student’s t-test, except for the in vivo growth factor inhibitor 
experiment, for which a one-way ANOVA with Tukey post-test was utilized. All tests were two-
sided with the threshold for significance defined as P < 0.05. For array analysis, adjusted p-
values were calculated using the Benjamini Hochberg method. Comparisons that remained 
significant using this correction method are indicated with an asterisk within the tables. 
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2.0  HGF INDUCES PULMONARY VASCULARIZATION 
2.1 INTRODUCTION 
Lung cancer is the number one cause for cancer-related deaths in men and women in the United 
States, accounting for 15% of new cancer diagnoses and 28% of all cancer deaths (1). 
Therapeutic options for patients are limited and new approaches are necessary to improve 
prognosis. NSCLC accounts for more than 80% of all lung cancers, and is dependent on 
angiogenesis (88, 89). The inhibition of angiogenesis is expected to prevent both the growth of 
tumor cells and emergence of tumor progression, thereby improving the prognosis of patients 
with NSCLC (17). The VEGF pathway is considered one of the major regulators in angiogenesis 
in normal and malignant tissues (89). However, resistance to anti-VEGF therapies and a lack of 
substantial clinical benefit with such treatments has been reported in NSCLC (17, 19). Recent 
evidence suggests that other pathways such as interleukins and HGF/c-Met signaling are 
sufficient to promote angiogenesis (20, 90, 91).  
While induction of VEGF in response to HGF has been reported, HGF has also been 
shown to induce neovascularization independently of VEGF (20, 92). For example, HGF-
dependent signaling through c-Met expressed on lymphatic endothelial cells is known to directly 
promote blood vessel formation during tissue repair, and does not require VEGFs (93). HGF can 
activate integrins on endothelial cells to trigger development of the lymph vascular system with 
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endothelial cell proliferation, survival, and migration (92). HGF also activates macrophages, 
which express the c-Met protein; macrophages can trigger angiogenic processes through release 
of cytokines such as IL-8 (94).  
In normal cells, c-Met activation is a transient event, whereas in tumor cells c-Met 
activity may be up-regulated by both receptor and ligand over-expression (68, 95). Over-
expression of HGF and c-Met has been reported in nearly 50% of lung adenocarcinomas (67-69), 
and is a strong independent prognostic factor in various cancers including lung, breast, biliary 
tract, gastric, and nasopharyngeal carcinoma (70-72). The strong correlation between HGF/c-Met 
expression and patient survival, coupled with its limited effect on normal adult tissue processes, 
advocates HGF/c-Met signaling as a useful therapeutic target with few adverse effects.  
To better understand the effects of HGF/c-Met signaling pathway in lung cancer, we 
previously generated transgenic mice with elevated HGF expression in the airway epithelium 
under the control of the Clara cell secretory protein promoter (86). We previously documented 
that when exposed to the tobacco carcinogen, NNK, the HGF TG mice exhibited a significant 
increase in tumor multiplicity compared to WT littermates (86). In that study, we observed high 
pulmonary blood vessel production in HGF TG mice after NNK exposure. Here we further 
characterize the vessel formation in HGF TG versus WT animals. Furthermore, to analyze which 
genes contribute to the differences in blood vessel formation, we profiled the expression of genes 
representative of pathways involved in angiogenesis and tumorigenesis using commercial 
microarrays from individual untreated lungs as well as from lung tumors that arose in NNK-
treated HGF TG and WT mice.  
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2.2 RESULTS 
2.2.1 HGF Over-expression Results in Enhanced Blood Vessel Formation. 
H&E staining and PECAM immunohistochemistry were used to compare blood vessel density in 
the lungs of HGF TG and WT mice. Blood vessels, indicated by PECAM, were counted in five 
high-magnification areas per lung from HGF TG (n=5) and WT (n=5) mice at 10, 20, and 40 
weeks of age. A considerable excess of blood vessels was observed by both H&E (Figure 4A and 
4B) and PECAM (Figure 4C and 4D) staining in the lungs of HGF TG (Figure 4B and 4D) mice 
compared to WT littermates (Figure 4A and 4C). This increase in blood vessel production was 
consistently seen in the lungs of HGF TG mice at all time points (10-40 weeks). The ratio of 
TG:WT blood vessel density was calculated and shown to increase over time (Figure 4E). The 
maximal effect occurred at 40 weeks with more than a 4-fold increase in blood vessel density in 
HGF TG mice (24.6 ± 3.9 microvessels/area) compared to WT lungs (5.8 ± 1.6 
microvessels/area, P=0.0022, Figure 4E). 
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Figure 4. Enhanced blood vessel formation in HGF TG mice vs. WT littermates. Representative 
pictures from 20 wk old WT (A,C) and HGF TG (B,D) mouse lungs. A,B. H&E staining. C,D. PECAM 
immunohistochemistry. Arrows indicate areas of increased blood vessel formation. E. Average number of 
blood vessels ± standard error from 5 high-magnification areas per lung of 5 HGF TG and 5 WT mice per 
time point. Asterisk denotes level of significance of HGF TG to similarly aged WT mice (* <0.05, ** 
<0.005, *** <0.001) 
 
 
2.2.2 Pulmonary Endothelial Cells Express c-Met Receptors. 
Pulmonary endothelial cells in WT mice are known to express c-Met receptors. C-Met 
immunohistochemistry was performed to confirm c-Met expression by pulmonary vessel 
endothelial cells in transgenic mice. As expected, endothelial cells stained positive for c-Met in 
both WT and HGF TG lungs (Figure 5). There was no difference in the percentage of c-Met 
positive endothelial cells between HGF TG and WT lungs. C-Met staining in blood vessels of 
HGF TG animals did however appear more intense compared to the staining in WT vessels. This 
could be due to an increase in number of receptors in the HGF TG vessels. HGF has been 
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reported to up-regulate its own receptor (96). The expression of c-Met receptor in endothelial 
cells of both HGF TG and WT mice suggests these vessels are able to directly respond to HGF 
stimulation.  
 
 
  
 
Figure 5. C-Met immunostaining. Representative pictures from WT and HGF TG mouse lungs. 
Endothelial cells in both HGF TG and WT mice stain positively for c-Met. 
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2.2.3 HGF Stimulated Vessels Show a Lesser Degree of Maturation. 
The PECAM immunohistochemistry results suggest that HGF over-expression continuously 
stimulated microvessel formation as mice aged. To confirm this, the degree of vessel maturation 
was examined at an intermediate time point (20 weeks of age), when enhanced vessel growth 
was incomplete. Nascent endothelial tubes form prior to pericyte coverage (97). The acquisition 
of pericytes indicates vessel stabilization and maturation (97). PECAM, as a pan-endothelial 
marker, does not distinguish vessel maturity. Only mature, pericyte containing vessels stain 
positive with SMA, a pericyte marker (98, 99). Whole lungs from HGF TG (n=6) and WT (n=6) 
mice were dual stained with SMA and PECAM to determine the average number of mature 
vessels (WT=4.05 ± 1.43), TG=6.33 ± 1.54) and total vessels (WT=5.02 ± 1.72, TG=9.42 ± 
1.86) per area. Representative images are shown in Figure 6A. The percentage of SMA positive 
vessels was determined by dividing the average number of SMA stained vessels by PECAM 
stained vessels in HGF TG and WT animals. A significantly smaller fraction of vessels stained 
positive for SMA in HGF TG mice (67 ± 1.8% SMA positive vessels) compared to WT 
littermates (80 ± 2.9% SMA positive vessels, P=0.0032, Figure 6B). These data demonstrate an 
increase in immature blood vessels in the lungs of HGF compared to WT littermates. This further 
suggests, blood vessel formation is continued throughout the animal’s lifespan and not 
completed at earlier development.  
 31 
 
Figure 6. Decreased blood vessel maturity in HGF TG mice compared to WT littermates. A. 
Representative pictures of dual immunofluorescent staining of the blood vessel marker, PECAM-1 
(green), and pericyte marker, SMA (red), from 20 wk old WT and HGF TG mouse lungs. B. Vessels 
stained with PECAM or SMA were counted in 5-10 high-magnification areas per lung of 6 HGF TG and 
6 WT mice. Graph depicts the % of SMA positive vessels as determined by dividing average number of 
SMA vessels by PECAM vessels in HGF TG or WT mice. Asterisk denotes level of significance of HGF 
TG to similarly aged WT mice (** <0.005) 
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2.2.4 Over-expression of HGF Increases Lymphatic Vessel Formation. 
HGF ligand has been reported as a major inducer of lymphangiogenesis (100). Since lymphatic 
endothelial cells also express PECAM-1, PECAM staining alone is unable to differentiate 
between blood and lymph microvessels. In order to determine if HGF-induced blood vessel 
formation included increased lymphatic vessel formation, lung tissues were stained for lymphatic 
vessel endothelial hyaluronan receptor-1 (LYVE-1). LYVE-1 is a cell surface receptor 
specifically expressed on lymphatic endothelial cells (101), and has been used as a marker for 
lymphangiogenesis in cancer (102, 103). Following LYVE-1 immunohistochemistry (Figure 7A 
and 7B), vessels were counted in ten high-magnification areas per lung from HGF TG (n=6) and 
WT (n=6) mice at 20 weeks of age. An excess of lymphatic vessels was observed in HGF TG 
(9.05 ± 0.2 vessels/1mm2) animals compared to WT (6.32 ± 0.3 vessels/1mm2, P=0.0001) 
littermates. The ratio of TG:WT lymphatic vessel density at 20 weeks of age was calculated as 
1.43 (Figure 7C). This is compared to a ratio of 3.33 for all vessels as determined by PECAM 
staining at 20 weeks of age (Figure 4E). Thus, vessels arising from the lymphatics accounted for 
at least part of the total increase in vessel density.   
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Figure 7. HGF TG mice displayed significantly higher numbers of LYVE-1 positive vessels than 
similarly aged WT littermates. A,B. Representative pictures from 20wk old WT (A) and HGF TG (B) 
mouse lungs stained with the lymphatic vessel marker, LYVE-1. C. Average number of LYVE-1 positive 
vessels from 10 high-magnification areas (1mm2) per lung of 6 HGF TG and 6 WT mice. Asterisk 
denotes level of significance of HGF TG to WT mice (*** <0.001). 
 
 
2.2.5 Several Angiogenic Factors are Down-regulated in HGF TG Animals Compared to 
WT littermates. 
Cancer Pathway Finder Array 
We profiled the expression of 113 genes using the Oligo GEArray Cancer Pathway Finder 
microarray to determine changes in gene expression associated with the enhanced 
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vascularization in HGF TG animals. Microarrays were completed using intact whole lungs from 
HGF TG (n=4) and WT (n=4) non-NNK treated mice (40 weeks of age, Table 2 and Appendix 
Table 5). The significance threshold was set at a 1.5- or 2.0-fold difference relative to wild-type. 
Genes are listed in order from most to least changed as determined by the HGF TG to WT ratio, 
along with the gene symbol, functional grouping, average expression as normalized to Gapdh, 
standard deviation, and P value. Six cancer-related pathways are represented on the array (Cell 
Cycle Control & DNA Damage Repair, Apoptosis and Cell Senescence, Signal Transduction 
Molecules and Transcription Factors, Adhesion, Angiogenesis, and Invasion and Metastasis), of 
which, mRNA expression was preferentially altered in genes involved in angiogenesis (16 of 32 
genes were down-regulated). Included in those 16 genes, all members of the VEGF family of 
angiogenic ligands were significantly reduced (Vegfd P=0.0031, Vegfb P=0.0043, Vegfa P=0.01, 
Vegfc P=0.0361, Table 2). Ratios of TG:WT expression for the four VEGF genes were as 
follows: Vegfd 0.34, Vegfb 0.48, Vegfa 0.53, Vegfc 0.56 (Table 2). The majority of genes on the 
Cancer Pathway Finder Array were not significantly different in the HGF TG murine lungs 
compared to WT lung, and none were up-regulated above the 2-fold boundary.  
By immunohistochemistry, the c-Met receptor protein appeared somewhat higher in the 
HGF TG vessels compared to WT mice. The c-Met receptor was included in the microarray, but 
was not significantly altered in HGF TG animals (Appendix Table 5). The localized change of c-
Met receptor within the microvessels may not be reflected in RNA isolated from whole lungs. 
We also observed that the murine HGF gene was down-regulated (2-fold), although not 
significantly, in HGF TG lungs compared to WT littermates (Appendix Table 5). This is not 
unexpected since the transgene is for human HGF. We have previously documented Clara cell-
specific over-expression of human HGF in the airways and bronchoalveolar lavage fluid of the 
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HGF TG animals (86). We would not expect an increase in murine HGF. The decrease in murine 
HGF may reflect feedback inhibition due to over-expression of the human HGF transgene. 
 
Table 2. Genes with significantly altered expression (>1.5-fold)  
    HGF WT HGF TG     
Symbol Functional Gene Grouping Avg STD Avg STD Ratio (TG:WT) p 
10 weeks 
 Epas1 Transcription Factor 6.38 0.69 0.76 0.11 0.12 0.0038* 
 Cdh5 Adhesion Molecule 2.78 1.03 0.35 0.22 0.12 0.0018* 
 Kdr Growth Factor Receptor 1.33 0.69 0.17 0.07 0.13 0.0017* 
 Tbx4 Transcription Factor 0.16 0.74 0.02 0.08 0.13 0.0018* 
 Eng Adhesion Molecule 0.60 0.61 0.09 0.10 0.15 0.0039 
 Tgfb1 Growth Factor 0.28 0.68 0.04 0.10 0.16 0.0001* 
 Ephb4 Growth Factor Receptor 0.31 0.66 0.05 0.14 0.17 0.0006* 
 Lama5 Adhesion Molecule 0.18 0.70 0.04 0.12 0.21 0.0119 
 Mmp2 Invasion & Metastasis/Protease 0.88 0.55 0.22 0.14 0.25 0.0082* 
 Fgfr3 Growth Factor Receptor 0.58 0.72 0.15 0.13 0.26 0.0067* 
 Flt1 Growth Factor Receptor 0.40 0.68 0.10 0.18 0.26 0.0009* 
 Npr1 Growth Factor Receptor 0.12 0.71 0.03 0.14 0.29 0.0029* 
 Timp2 Invasion & Metastasis/ Angiogenic Inhibitor Protein 1.95 0.67 0.65 0.13 0.33 0.0103 
 Col4a3 Matrix Protein 0.12 0.97 0.04 0.35 0.35 0.0390 
 Mapk14 Growth Factor Receptor 0.19 0.65 0.07 0.10 0.38 0.0267 
 Stab1 Adhesion Molecule 0.10 0.64 0.04 0.20 0.40 0.0063* 
 Tgfb2 Growth Factor 0.07 0.48 0.03 0.17 0.40 0.0172 
 Pecam1 Adhesion Molecule 2.85 0.64 1.25 0.15 0.44 0.0035* 
 Sphk1 Transcription Factor 0.02 0.67 0.01 0.20 0.46 0.0004* 
 Pdgfa Growth Factor 0.17 0.68 0.08 0.28 0.46 0.0017* 
 Mmp9 Invasion & Metastasis/Protease 0.06 0.77 0.03 0.18 0.46 0.0391 
 Nrp2 Growth Factor Receptor 0.15 0.70 0.07 0.19 0.49 0.0333 
 Tnfsf12 Adhesion Molecule 0.14 0.60 0.07 0.21 0.54 0.0017* 
 Plau Invasion & Metastasis/Protease 0.02 0.71 0.01 0.20 0.63 0.0445 
 Ptgs1 Signal Transduction Molecule 0.38 0.63 0.25 0.23 0.65 0.0161 
 Cxcl5 Cytokine 0.00 0.42 0.02 0.23 4.89 0.0252 
 Il1b Cytokine 0.22 0.51 1.35 0.34 6.04 0.0343 
40 weeks               
Efna2 Signal Transduction Molecule 0.48 0.27 0.09 0.17 0.19 0.0286 
Pik3cb Signal Transduction Molecule 0.57 0.10 0.11 0.05 0.20 0.0285 
Cxcl9 Cytokine 0.35 0.19 0.08 0.10 0.23 0.0304 
Mmp9 Invasion & Metastasis/Protease 0.25 0.15 0.08 0.01 0.34 0.0250 
Figf (Vegfd) Growth Factor 0.51 0.13 0.18 0.16 0.34 0.0031 
Akt1 Signal Transduction Molecule 0.56 0.14 0.20 0.12 0.36 0.0013 
angptl4 Angiogenic Inhibitor Protein 0.63 0.21 0.25 0.18 0.40 0.0324 
Syk Signal Transduction Molecule 0.16 0.02 0.07 0.00 0.41 0.0172 
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Table 2 Continued…       
    HGF WT HGF TG   
Symbol Functional Gene Grouping Avg STD Avg STD Ratio (TG:WT) p 
Mmp2 Invasion & Metastasis/Protease 0.29 0.06 0.13 0.05 0.44 0.0004 
Pofut1 Signal Transduction Molecule 0.22 0.07 0.10 0.03 0.44 0.0143 
Tnfrsf12a Adhesion Molecule 0.41 0.13 0.18 0.11 0.45 0.0376 
Vegfb Growth Factor 0.69 0.18 0.33 0.15 0.48 0.0043 
Efna1 Signal Transduction Molecule 0.42 0.04 0.20 0.17 0.49 0.0459 
TNF Cytokine 0.17 0.04 0.08 0.02 0.49 0.0008 
Pik3r1 Signal Transduction Molecule 0.13 0.02 0.06 0.00 0.49 0.0425 
Nrp2 Growth Factor Receptor 0.19 0.04 0.10 0.02 0.52 0.0055 
Mdk Growth Factor 0.21 0.05 0.11 0.03 0.53 0.0107 
Tgfb3 Growth Factor 0.72 0.15 0.38 0.19 0.53 0.0327 
Vegfa Growth Factor 0.83 0.11 0.45 0.28 0.53 0.0100 
Mapk14 Growth Factor Receptor 0.89 0.10 0.48 0.35 0.54 0.0205 
Flt1 Growth Factor Receptor 0.89 0.10 0.48 0.35 0.54 0.0205 
Csf3 Cytokine 0.32 0.09 0.18 0.07 0.55 0.0422 
Vegfc Growth Factor 0.23 0.08 0.13 0.06 0.56 0.0361 
Timp3 Invasion & Metastasis/ Angiogenic Inhibitor Protein 0.94 0.08 0.53 0.28 0.56 0.0065 
Grb2 Signal Transduction Molecule 0.11 0.00 0.06 0.00 0.57 0.0046 
Anpep Protease 0.11 0.03 0.07 0.02 0.58 0.0344 
Plau Invasion & Metastasis/Protease 0.11 0.04 0.06 0.01 0.60 0.0457 
Col18a1 Angiogenic Inhibitor Protein 0.13 0.03 0.08 0.03 0.62 0.0166 
Ptgs2 Signal Transduction Molecule 0.12 0.03 0.07 0.01 0.62 0.0328 
Itga2 Adhesion Molecule 0.10 0.00 0.06 0.00 0.64 0.0069 
Pdgfa Growth Factor 0.93 0.08 0.60 0.28 0.65 0.0198 
Timp1 Invasion & Metastasis/ Angiogenic Inhibitor Protein 0.11 0.03 0.07 0.01 0.65 0.0169 
Eng Adhesion Molecule 0.09 0.02 0.06 0.01 0.65 0.0357 
FGF1 Growth Factor 0.09 0.03 0.06 0.01 0.66 0.0350 
IGF1 Growth Factor 0.10 0.02 0.07 0.01 0.67 0.0019 
*adjusted p-value <0.05 after application of Benjamini Hochberg correction 
 
 
 
Angiogenesis Array 
In order to look more closely at which genes may be responsible for the enhanced 
vascularization, we profiled the expression of 113 genes involved in angiogenesis using 
commercial angiogenic arrays (Oligo GEArray and Angiogenesis PCR Array) (Figure 8A and 
8B). Microarrays were completed on individual whole lungs from HGF TG and WT non-NNK 
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treated animals of 10 weeks (HGF TG, n=4; WT, n=3) and 40 weeks (HGF TG, n=4; WT, n=4) 
of age. Twenty-five genes, including VEGF receptor 2 (Kdr), neuropilin 1 (Nrp1), and 
transforming growth factor beta 2 (Tgfb2) showed a significant 2-fold decrease in expression in 
HGF TG mice compared to WT littermates at 10 weeks of age. Also at 10 weeks, a significant 
increase was seen in two pro-angiogenetic genes: chemokine (C-X-C motif) ligand 5 (Cxcl5) and 
Il1b (Table 2). At 40 weeks of age, a significant 2-fold decrease was seen for the expression of 
eight of the same genes as at 10 weeks, such as, Mmp2, Mmp9, and neuropilin 2 (Nrp2) (Table 
2). An additional 21 other genes associated with angiogenesis were also reduced at 40 weeks 
including angiopoietin-like 4 (Angptl4), Cxcl9, Tgfb3, Figf (Vegfd), Vegfa, Vegfb, and Vegfc 
(Table 2). No genes were found to be up-regulated above the 2-fold level at 40 weeks of age. 
Lung tissue was also analyzed from mice sacrificed at 20 weeks of age. Similar trends were 
observed in the decreased gene expression comparable to those seen at 10 and 40 weeks, though 
the changes at 20 weeks were not significant (data not shown). The Benjamini Hochberg method 
was applied to control for the false-discovery rate, due to the number of mRNA transcripts 
examined. Comparisons with adjusted p-values that remained significant are indicated with an 
asterisk within the tables. Since the normalized array data demonstrated reproducible results on 
both arrays, the chance of spurious result is small. Thus, p-values that did not remain significant 
after Benjamini Hochberg analysis are not necessarily false. 
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Figure 8. Whole Lung DNA Microarrays and Western Blot Analysis for genes related to 
angiogenesis. Microarray Analysis depicted decreased expression in genes associated with angiogenesis 
in HGF TG mice compared to WT littermates. A,B. Scatter Plot analysis displaying the fold difference in 
the relative expression levels of genes in the angiogenesis array from 10 wk (A) and 40 wk (B) HGF TG 
mice vs. WT. A green (+) represents genes whose fold decrease is greater than the 2-fold boundary. Black 
asterisks depict unchanged genes. C,D. Protein expression of individual whole lungs from 10 wk (C) and 
40 wk (D) old HGF TG and WT mice. Relative densitometry quantitation normalized to β-actin is shown 
beneath each lane. 
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 A two-dimensional clustergram of the individual lung tissue expression profiles (at 40 
weeks) from the angiogenesis array was generated using the normalized expression and an 
average join type. Individual HGF TG samples were successfully clustered from the WT lungs 
(Figure 9). VEGF signaling pathway genes shown to be reduced in HGF TG lungs compared to 
WT by scatterplot were also identified by clustergram and statistical analyses: Vegfa, Vegfb, 
Vegfc, Vegfd/Figf, Nrp2, Csf3, Pi3k, and Grb2. The large majority of genes on the angiogenesis 
array were not significantly different between WT and HGF TG lungs. Those genes with an 
expression ratio (TG:WT) of at least 0.80 at both 10 and 40 weeks include epidermal growth 
factor (Egf), angiopoietin 1 (Angpt1), fibroblast growth factor 2 (Fgf2), integrin alpha 5 (ItgaV), 
matrix metallopeptidase 19 (Mmp19), and serpin peptidase inhibitor clade F member 1 (Serpinf1) 
(Appendix Table 5). 
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Figure 9. Angiogenesis clustergram. Samples are clustered by gene expression similarity. More similar 
genes appear lower on the dendrogram and less similar at higher heights. Colored arrows point to the 
genes of interest indicated by the legend. 
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Western Analysis 
Western blot analysis verified several genes whose expression was decreased on the microarrays. 
Protein was extracted from whole lung tissue from the same mice utilized for the microarray 
analysis. The VEGFA, VEGFD, and AKT1 genes, identified as down-regulated in microarray 
analysis at 10 weeks (Figure 8A) and 40 weeks (Figure 8B), demonstrated reduced protein 
expression in HGF TG mice compared to WT littermates at both 10 (Figure 8C) and 40 (Figure 
8D) weeks of age. The following percent decrease in protein expression was determined after 
normalizing to ß-actin: VEGFA (40.2% 10 weeks, 62.4% 40 weeks), VEGFD (73.3% 10 weeks, 
94.4% 40 weeks), and AKT1 (60.2% 10 weeks, 49.7% 40 weeks). Verification of microarray 
results by protein analysis at multiple time points further suggests that genes found statistically 
significant before exclusion by the Benjamini Hochberg method are not necessarily false. 
2.2.6 VEGFR2 Inhibition does not Block Increased Vascularization in HGF TG animals. 
Expression data demonstrated VEGF mRNA and protein was significantly reduced in HGF TG 
mice compared to WT littermates at 40 weeks of age and down-regulated or found at comparable 
levels at 10 weeks of age. Thus, the increased vascularization seen in HGF transgenic animals is 
expected to be largely VEGF-independent. To further confirm that VEGF is not required for 
enhanced blood vessel formation in vivo, WT and HGF TG mice were treated with vandetanib. 
Vandetanib is a tyrosine kinase inhibitor of VEGFR2/3 (104). VEGFR3 is the major receptor 
responsible for endothelial cell proliferation in response to VEGF stimulation (104). To a lesser 
extent, Vandetanib also inhibits EGFR (104). To account for this, mice were also treated with 
gefitinib, a selective EGFR inhibitor. Any differences observed in vascularization after 
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vandetanib treatment, which were not observed with gefitinib treatment, could be attributed to 
VEGF inhibition exclusively.  
HGF TG (n=3) and WT (n=3) littermates were treated with vehicle control (1% Tween-
80/0.9% saline), gefitinib (75mg/kg), or vandetanib (25mg/kg) for five weeks, beginning at five 
weeks of age. Whole lungs were collected at 10 weeks of age and sectioned for PECAM 
immunohistochemistry. A significant increase of blood vessel density was seen in HGF TG 
animals compared to WT littermates regardless of treatment (Table 3). Vandetanib and gefitinib 
treatments had no effect on normal microvessel density in WT mice (5.52 ± 0.33 
microvessels/area, 6.52 ± 0.36 microvessels/area respectively) as compared to control WT 
littermates (4.63 ± 0.28 microvessels/area (n.s., vandetanib or gefitinib vs. control)). As 
expected, blood vessel density was significantly increased in control HGF TG mice at 10 weeks 
(8.00 ± 0.48 microvessels/area) compared to control WT littermates (4.63 ± 0.28 
microvessels/area, P<0.001). Vandetanib treatment did not modify microvessel density in HGF 
TG mice (8.79 ± 0.59 microvessels/area) compared to control HGF TG animals (8.00 ± 0.48 
microvessels/area, P > 0.05). Blood vessel density in HGF TG lungs from vandetanib treated 
mice remained significantly increased from WT mice either with or without vandetanib treatment 
(P < 0.001 for both comparisons). Gefitinib treatment slightly increased microvessel density in 
HGF TG mice (10 ± 0.42, P=0.049), compared to control transgenic animals. Thus, inhibiting 
EGFR in the presence of HGF over-expression slightly promotes new blood vessel formation. 
Gefitinib has been reported to inhibit recruitment of pericytes to blood vessels (105). By 
maintaining blood vessels in an immature state, endothelial cell growth and migration could be 
continued in the presence of elevated HGF. These data further establish that VEGF pathways do 
not play a major role in microvessel formation in the lungs when HGF/c-Met activation is high.  
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Table 3. Blood vessels per area comparison. 
Treatment WT HGF TG 
Vehicle 4.6 ± 0.3 8.0 ± 0.5 
Gefitinib 6.5 ± 0.4 10 ± 0.4 
Vandetanib 5.5 ± 0.3 8.8 ± 0.6 
Comparisons Mean Difference p 
Vehicle WT vs Vehicle TG -3.37 < 0.001 
Vehicle WT vs Gefitinib WT -1.89 > 0.05 
Vehicle WT vs Vandetanib WT -0.89 > 0.05 
Vehicle WT vs Vandetanib TG -4.15 < 0.001 
Vehicle TG vs Gefitinib TG -2.00 < 0.05 
Vehicle TG vs Vandetanib TG -0.78 > 0.05 
Gefitinib WT vs Gefitinib TG -3.48 < 0.001 
Vandetanib WT vs Vandetanib TG -3.26 < 0.001 
 
 
 
2.2.7 Lung Tumors from Transgenic Mice Demonstrate a Similar Decrease in Angiogenic 
Genes as Whole Lung Analysis, with Increased Expression of Inflammatory Related Genes.  
All of the previously discussed work was carried out on whole lungs of HGF TG and WT 
animals. To determine if lung tumors demonstrate similar patterns of down-regulated angiogenic 
genes, HGF TG and WT mice were injected with NNK and individual tumors were collected. 
Microarray analysis on tumors from HGF TG mice (n=4) was compared to lung tumors from 
WT mice (n=4). Representative arrays from HGF TG and WT are shown in Figure 10. Many of 
the same genes, which were found to be down-regulated in HGF TG whole lung, showed a 
significant 2-fold or greater decrease in expression in HGF TG tumors compared to WT tumors. 
The down-regulated genes included Mmp2, Akt1, Timp3, and the Vegfa, Vegfb, Vegfc, and 
Vegfd/Figf (Figure 10B). The majority of genes on the both the Cancer Pathway Finder and 
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Angiogenesis Arrays were shown to have comparable expression between HGF TG and WT 
individual tumors (Table 4). Three genes had a high TG:WT ratio in whole lung expression; 
Angptl1, Fgf2, and ItgaV. These three genes also showed a ratio of 1.0 or higher in HGF TG 
tumors compared to WT tumors (Table 4). Five genes were found to be significantly up-
regulated in the HGF TG tumors compared to WT tumors. All five belong to the chemokine (C-
X-C motif) ligand family: Cxcl1, Cxcl2, Cxcl10, Cxcl11, and Cxcl9 (Table 4). Cxcl1 and Cxcl2 
are murine homologs of IL8, a potent angiogenic chemokine.  
 
 
Table 4. Expression of genes in HGF TG lung tumors. 
  WT Tumor TG Tumor     
Symbol Avg STD Avg STD Ratio (TG:WT) p 
Angiogenesis Array 
Cxcl1 0.16 0.01 0.41 0.01 2.55 0.002* 
Cxcl11 0.15 0.01 0.32 0.01 2.21 0.002* 
Cxcl10 0.25 0.02 0.45 0.01 1.79 0.006 
Cxcl2 0.17 0.02 0.30 0.00 1.75 0.010 
Cxcl9 0.43 0.04 0.73 0.00 1.71 0.008 
Ifng 0.18 0.01 0.26 0.00 1.46 0.084 
Il1b 0.63 0.06 0.78 0.01 1.24 0.677 
Tnfaip2 0.27 0.04 0.32 0.02 1.20 0.994 
Cxcl5 0.11 0.00 0.11 0.00 1.01 0.405 
Cancer Array 
Fgfr2 0.12 0.01 0.15 0.04 1.19 0.497 
Mmp9 0.15 0.01 0.18 0.08 1.17 0.690 
Atm 0.11 0.01 0.12 0.01 1.17 0.142 
Cdh1 0.41 0.19 0.46 0.13 1.14 0.756 
Birc5 0.09 0.00 0.10 0.02 1.13 0.538 
Cdc25a 0.28 0.00 0.31 0.01 1.11 0.072 
Bai1 0.08 0.01 0.09 0.02 1.09 0.690 
Cflar 0.13 0.01 0.14 0.03 1.08 0.686 
Brca1 0.11 0.00 0.12 0.02 1.06 0.600 
Cdk2 0.10 0.01 0.11 0.01 1.05 0.714 
Bak1 0.17 0.01 0.18 0.01 1.04 0.541 
Ifna1 0.14 0.01 0.14 0.01 1.03 0.561 
Ccne1 0.17 0.01 0.17 0.02 1.03 0.826 
E2f1 0.09 0.01 0.10 0.02 1.03 0.887 
Angpt1 0.10 0.01 0.11 0.02 1.02 0.843 
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Table 4 Continued…    
  WT Tumor TG Tumor   
Symbol Avg STD Avg STD Ratio (TG:WT) p 
Cd44 0.52 0.12 0.53 0.09 1.02 0.919 
Brca2 0.10 0.00 0.10 0.02 1.02 0.857 
Fgf2 0.09 0.00 0.09 0.02 1.02 0.914 
Icam1 0.75 0.06 0.76 0.10 1.01 0.902 
Tgfb1 0.80 0.08 0.81 0.05 1.01 0.882 
Cdk4 0.93 0.03 0.94 0.01 1.01 0.775 
ItgaV 0.09 0.01 0.09 0.02 1.00 0.996 
Ifnb1 0.09 0.01 0.09 0.02 1.00 0.997 
Tnf 0.14 0.00 0.14 0.05 1.00 0.998 
*adjusted p-value <0.05 after application of Benjamini Hochberg correction 
 
 
 
 
Figure 10. Tumor DNA Microarray Analysis for genes associated with angiogenesis. Similar patterns 
of down-regulated gene expression were seen in NNK induced tumors from HGF TG mice compared to 
WT littermates. A. Representative hybridization blots from HGF TG and WT mice. Colored boxes 
highlight specific significantly down-regulated genes. B. Scatter plot displaying the fold difference in the 
relative expression levels of genes of isolated NNK induced lung tumors from HGF TG and WT mice (40 
weeks old). A green (+) represents genes whose fold decrease is greater than the 2-fold boundary. Black 
(+) depicts unchanged genes. Red (+) represents genes whose fold increase is greater than the 2-fold 
boundary. Colored arrows point to corresponding genes as indicated on microarray blots. 
 46 
2.3 CONCLUSIONS AND DISCUSSION 
 
Although the angiogenesis process in lung cancer has been considered to be largely dependent on 
the VEGF pathway (88, 89), our results support the hypothesis that different signaling pathways 
can drive vessel formation. Lungs, in the presence of high HGF expression, demonstrated 
vigorous and constant increasing vascularization compared to wild-type littermates. These 
vessels uniformly expressed c-Met protein, and thus are able to respond to increased HGF ligand 
directly. We observed that microvessels in HGF over-expressing mice were significantly less 
mature than their WT counterparts. These data support the idea that HGF ligand continually 
enhances blood vessel formation over time. In addition to blood vessel enhancement, HGF over-
expression was shown to induce lymphatic vessel growth. Lymphatic vessels, which are known 
to be stimulated by HGF (100), accounted for one-third of the total enhanced vessel density in 
this study.   
Gene expression analysis produced mRNA profiles for HGF TG and WT animals. The 
lungs of HGF TG mice displayed significantly reduced gene expression in pro-angiogenic 
molecules such as the VEGF family and genes associated with the VEGF pathway such as Nrp2. 
This pattern of decreased expression was seen in HGF TG mice compared to WT littermates 10, 
20, and 40 weeks of age. Western blot analysis confirmed that VEGF genes maintained reduced 
protein levels in 10 and 40 week HGF over-expressing mice compared to WT. Furthermore, 
vandetanib treatment of HGF TG mice at an early age failed to inhibit the enhanced 
vascularization documented in HGF TG animals. This further suggests HGF acts independently 
of VEGF pathway to stimulate vascularization. There was no significant change in the genes 
related to apoptosis, proliferation, or oncogenic pathways contained in these arrays. Thus, in the 
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absence of injury, such as a carcinogenic treatment, HGF over-expression in the lungs of 
transgenic animals produces angiogenic effects over oncogenic signals; similar to the role HGF 
plays in wound healing. Previous observation revealed heterozygous HGF TG mice do not 
develop lung tumors spontaneously (86). Lung adenoma and adenocarcinoma formation remain 
dependent on carcinogen exposure.    
It is possible that HGF-induced vascularization occurs through transcription of genes not 
represented on the gene arrays utilized, thus accounting for the lack of up-regulated gene 
expression seen in this study. Alternatively, much of the increased in blood vessels could be 
through direct effects of the transgenic HGF protein on endothelial cells that do not require 
increased synthesis of the mRNAs examined. For example, HGF, via the c-Met receptor, could 
directly activate integrins expressed on endothelial cells to promote their movement and 
proliferation (92). Release of pre-synthesized angiogenic proteins from infiltrating macrophages 
and neutrophils, such a ELR+ CXC chemokines, also would not require new mRNA synthesis of 
angiogenic factors and could act directly on endothelial cell receptors (29). It is also possible that 
since the blood vessels were not microdissected for RNA extraction, we were only able to 
observe gene expression changes occurring in whole lung, and could not measure local changes 
in mRNAs needed for increased vascularization in response to HGF. 
Tumor gene expression data mimicked profiles seen in whole lung analysis. However, a 
significant increase in five chemokine (C-X-C motif) ligand family members was seen in HGF 
TG lung tumors compared to WT tumors. These included both pro-angiogenic ELR+ and 
angiostatic ELR- CXC chemokines. There was no significant change in mRNA expression for 
whole lung samples of the functional homologues of IL-8 (Cxcl2 and Cxcl1) or IL-1ß at 40 
weeks. A significant up-regulation of Cxcl5, another pro-angiogenic CXC chemokine, and IL-1ß 
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was seen in HGF TG mice at 10 weeks of age. IL-8 and IL-1ß have been identified as potential 
mediators for HGF-induced angiogenesis in HNSCC (33, 106), and nasopharyngeal cancer 
(NPC) (91). Co-expression of HGF and IL-8 in NPC has been shown to be associated with 
increased microvessel density and poor prognosis (91). HGF has also been reported to induce IL-
8 expression in lung adenocarcinoma cells (90). The increased expression of Cxcl1, Cxcl2, and 
IL-1ß in whole lung samples (10 weeks) and HGF TG tumors indicates these chemokines play a 
role in HGF-mediated normal vascularization as well as tumorigenesis in the lung. Angiostatic 
ELR- CXC chemokines were also up-regulated in HGF TG tumors, but to a lesser extent than 
pro-angiogenic ELR+ factors. This increase may be due to an attempt to balance the rise in pro-
angiogenic factors.  
There was no significant down regulation of genes such as caspase-9 or Bax that would 
imply decreased apoptosis is occurring in untreated HGF TG lungs. Additionally, no other genes 
related to proliferation or oncogenesis contained on these microarrays were found to be elevated. 
These results further suggest that in the absence of injury, angiogenic effects of HGF over-
expression predominate over oncogenic signals.  
Overall these results suggest the main effect of HGF over-expression in the transgenic 
mice is enhanced vascularization accompanied by reduced VEGF pathway genes in lung tissues. 
Decreases in VEGF may be a feedback mechanism in response to heightened microvessel 
density as stimulated by HGF. Down-regulation of VEGF through high HGF expression could 
explain resistance to anti-VEGF therapies currently being tested in several types of cancer 
including NSCLC (17, 19). Tumor inhibition by VEGF inhibitor in mice was not as effective in 
HNSCC cells that showed relative VEGF down-regulation (106). Also, elevated HGF levels 
were associated with colorectal cancer progression in patients being treated with bevacizumab 
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(21). Similarly, c-Met signaling plays a role in sunitinib resistance (19). Resistant tumors 
contained higher HGF concentrations and c-Met expression compared to sensitive tumors. In this 
study, dual treatment with sunitinib and a c-Met inhibitor significantly inhibited tumor growth 
compared to sunitinib alone and largely targeted the vasculature in resistant tumors (19).  
Our HGF TG mouse model could be used to further examine agents that selectively 
inhibit angiogenesis via VEGF-independent pathways, and lead to new insights into the 
pathogenesis of NSCLC. It would also be useful in the examination of new anti-angiogenic 
approaches, either through HGF/c-Met inhibition, or combination with VEGF inhibitors. The 
complete inhibition of angiogenesis in lung cancer may require novel compounds that target 
angiogenesis through multiple pathways.  
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3.0  DELAYED C-MET SIGNALING INDUCES P-STAT3 
3.1 INTRODUCTION 
Recent efforts in the battle against lung cancer have focused on targeting specific lung cancer-
related growth factor pathways such as the VEGFR and EGFR signaling pathways. 
Unfortunately there has been a lack of clinical efficacy reported for these inhibitors (51). 
Compensatory signaling from the HGF/c-Met pathway has been reported to play a role in the 
resistance to both VEGFR and EGFR inhibition (51). Acquired resistance to EGFR tyrosine 
kinase inhibitors (TKI) has been linked to c-Met in EGFR mutant lung cancer cells (51). 
Crosstalk between similar pathways has been described in several studies as one method for 
resistance to receptor blockade (75, 79). In these cases, as the tumor progresses, signaling shifts 
from one RTK to another. EGFR family members are co-expressed with c-Met receptors in 
many human tumors including NSCLC (78). Both pathways initiate similar downstream effector 
molecules such as PI3K/AKT, K-Ras/MAPK, and STAT. These pathways play critical roles in 
tumor growth and metastasis.  
Lateral signaling between c-Met and EGFR has been implicated to be required for cell 
migration, invasion, and survival (75, 80). Our laboratory has previously determined that 
crosstalk from the EGFR pathway results in a delayed and prolonged activation of c-Met 
signaling in NSCLC (80). Delayed c-Met activation by EGF was shown to mediate EGFR-
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induced invasion, motility, and proliferation. Early evidence suggests EGF induced delayed c-
Met signaling mediates alternative signaling cascades than those seen by HGF stimulation. We 
hypothesized that delayed c-Met activation amplifies EGF-induced invasion and migration 
through prolonged activation of mediators such as STAT3. Identification of mediators 
downstream of EGFR induced delayed c-Met signaling could make for ideal candidates for 
individual or combinational therapeutic targeting, in order to circumvent survival signaling to 
compensatory pathways in NSCLC. STAT3 was thought to be a likely candidate because it is 
known to mediate invasion in other systems. To address the hypothesis, the time course of 
STAT3 activation following EGFR stimulation and the mechanism of delayed STAT3 activation 
were studied.  
3.2 RESULTS 
3.2.1 EGFR Ligands Induce Biphasic Activation of STAT3 in NSCLC cells. 
EGFR ligands have been previously shown to induce delayed and prolonged phosphorylation of 
c-Met receptors in NSCLC cells (80). In that study, c-Met phosphorylation first appeared at 8 
hours and was sustained for 48 hours after treatment with EGF. STAT3 belongs to the group of 
STAT family transcription factors. When activated downstream of growth factors such as EGF 
and HGF, STAT family transcription factors up-regulate genes related to invasion and cell 
growth (107, 108). In order to determine whether STAT3 plays a role in delayed c-Met signaling, 
201T cells were treated with EGF or HGF for 0-24 hours. Protein lysates from several time 
points were collected and analyzed for STAT3 phosphorylation (Figure 11). Both HGF and EGF 
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stimulation induced phospho-STAT3 within 5 minutes. However, while HGF stimulated STAT3 
phosphorylation was quickly terminated (Figure 11A), EGF activated STAT3 in a biphasic 
manner (Figure 11B). While initial activation of STAT3 was reduced to near baseline levels 2 
hours post-treatment, a second wave of activation was initiated 8 hours post-treatment and was 
sustained for 24 hours. This biphasic regulation of STAT3 phosphorylation by EGF mimics the 
pattern of c-Met and c-Src phosphorylation previously noted by our laboratory (80).  
 
 
 
Figure 11. EGFR ligands induce biphasic activation of STAT3. 201T and H1435 cells were serum 
deprived 48 hours prior to treatment with (A) HGF (10ng/mL) or (B) EGF (10nM) for the indicated time 
points. Cell lysates were analyzed for STAT3 phosphorylation and expression.   
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Activated STAT proteins must dimerize and translocate to the nucleus in order to bind to 
specific target gene promoters (107, 108). To confirm that the delayed phosphorylation of 
STAT3 by EGF resulted in biologically active STAT3, nuclear lysates from time course 
experiments with 201T cells were collected and analyzed for STAT3 phosphorylation. A pattern 
of biphasic phosphorylation was seen in the nuclear extracts similar to that seen with whole cell 
lysates (Figure 12).  
 
 
 
 
 
Figure 12. EGFR simulated STAT3 transnuclear location mimics biphasic pattern. 201T cells were 
treated with EGF (10nM) for various time points after 48 hours serum starvation. Cell lysates were 
fractionated into nuclear and cytosolic portions and analyzed for phospho- and total STAT3 levels. PARP 
detection validated nuclear and cytoplasmic separation. Actin confirmed equal loading of gels.   
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3.2.2 Delayed Activation of STAT3 is downstream of c-MET. 
The pattern of STAT3 phosphorylation suggests an association between prolonged STAT3 
activation and delayed c-Met signaling following EGF stimulation. C-Met may be utilizing 
STAT3 to amplify and prolong signaling from EGFR. To further investigate whether c-Met 
activation was required for prolonged STAT3 phosphorylation, 201T cells were pre-treated with 
the specific c-Met inhibitor, PHA665752 (1 µM), for 2 hours followed by time course analysis of 
EGF stimulation. Inhibition of c-Met had no effect on the rapid EGF-induction of STAT3 
phosphorylation, suggesting early activation by EGFR signaling cascade is not affected by c-Met 
(Figure 14). However, inhibition of c-Met abolished the bisphasic pattern of STAT3 activation, 
reducing delayed phospho-STAT3 levels to baseline (Figure 13). This suggests that c-Met is 
required to prolong EGFR signaling through the STAT3 protein.  
 
 
 
Figure 13. C-Met is required for delayed phosphorylation of STAT3. 201T and H1435 cells were 
serum deprived for 48 hours. Cells were pretreated with PHA665752 (1µM), a Met inhibitor, for 2 hours 
followed by stimulation with EGF (10nM) for the indicated time points. Cell lysates were analyzed for 
total and phospho-STAT3 expression. 
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3.2.3 C-Src does not Mediate delayed c-Met Activation of STAT3. 
The biphasic regulation of STAT3 phosphorylation by EGF mimicked the pattern of c-Src 
phosphorylation previously noted by our laboratory (80). STAT3 activation via EGFR ligand 
stimulation has been well characterized and is believed to occur through a variety of mechanisms 
(108, 109), including direct interaction with c-Src. Sustained signaling from c-Met to c-Src could 
allow STAT3 to be continually phosphorylated, dimerized, and translocated to the nucleus for 
transcription up-regulation. In order to test if c-Src played a mediator role between c-Met and 
STAT3 activation, 201T cells were treated with EGF for 30 minutes prior to addition of a SFK 
inhibitor, PP2 (500nm). Lysates were collected 2-48 hours post-EGF stimulation. Since c-Src has 
been shown to be integral upstream of delayed c-Met activation (80), PP2 was added early 
enough to inhibit the second wave of Src activation, while still allowing for induction of 
phospho-Met. Inhibition of c-Src by PP2 at delayed time points had no effect on phospho-
STAT3 levels (Figure 14). PP2 treatment was effective as shown by successful inhibition of p-
Src (Figure 14). This suggests c-Src, while activated at delayed time points, does not mediate c-
Met signaling to STAT3 activation and translocation.    
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Figure 14. C-Src does not mediate EGFR-induced delayed activation of STAT3. 201T cells were 
serum starved 48 hours prior to stimulation with EGF (10nM). The c-Src inhibitor, PP2 (1µM), was added 
one hour post stimulation with EGF. Lysates were collected and analyzed for phospho- and total STAT3, 
or phospho- and total c-Src.   
 
 
 
3.2.4 C-Met Directly Interacts with STAT3. 
The involvement of c-Src as a mediator between c-Met and STAT3 activation was ruled out by 
the inability of PP2 to block delayed phospho-STAT3. While other effectors could potentially 
mediate c-Met signaling to STAT3 activation, direct association of STAT3 through its Src 
homology-2 (SH2) domain with c-Met can also result in its phosphorylation (110). Therefore, we 
examined whether c-Met interacts with STAT3 after exogenous EGF addition. Following EGF 
stimulation for 2-48 hours, co-immunoprecipitation of 201T lysates demonstrated that STAT3 
could associate with c-Met at delayed time points (Figure 15). This suggests that STAT3 
activation 8-48 hours after EGF stimulation is due to direct activation by c-Met. 
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Figure 15. STAT3 associates with c-Met at delayed time points. 201T cells were serum starved 48 
hours prior to time course stimulation with EGF (10nM). Lysates (400µg) were immunoprecipitated with 
total STAT3 or c-Met and blotted for c-Met or STAT3 respectively.  
 
 
 
3.3 CONCLUSIONS AND FUTURE DIRECTION 
While EGFR has been the focus of targeted therapeutics in NSCLC, resistance is common and 
lessens clinical value. Acquired resistance to EGFR has been linked to compensatory signaling 
from the HGF/c-Met pathway (51). Evidence of lateral signaling between EGFR and c-Met has 
been determined to occur in several cancer types (75, 79). Our laboratory recently discovered 
crosstalk from the EGFR pathway results in prolonged c-Met activation in NSCLC (80). Delayed 
c-Met signaling following EGF-stimulation appears to utilize separate mediators involved in 
tumorigenesis compared to transient activation. To date, delayed c-Met signaling has been shown 
to be independent of MAPK and AKT1 activation (80). The only molecule whose activation has 
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been identified to require EGFR to c-Met lateral crosstalk is STAT3. STAT3 is known to act 
downstream of HGF stimulated c-Met to control tublogenesis, wound healing, anchorage-
independent growth, and invasion (107). It also plays an important function in the invasive 
growth response to EGFR ligand stimulation. We previously determined that delayed c-Met 
activation was required to obtain maximal EGFR-induced invasion, motility, and proliferation in 
NSCLC cells (80). It is possible that EGFR utilizes c-Met to amplify downstream signaling 
cascades that are initially activated early on.  
The results from this study support the hypothesis that prolonged activation of STAT3, 
which is dependent on direct interaction with c-Met, may be a key mechanism responsible to 
produce maximal cell movement and invasion after EGFR activation (Figure 16). 
 
 
 
 
Figure 16. Model of EGFR-induced c-Met activation of STAT3 in NSCLC. 
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We demonstrated that STAT3 phosphorylation occurs downstream of delayed c-Met 
activation in NSCLC cell lines. A biphasic pattern of STAT3 activation appears when NSCLC 
cells are stimulated with EGFR ligands. Transient activation by EGFR at early time points is 
unaffected by c-Met inhibition. Yet, when delayed c-Met signaling was blocked by PHA665752 
phosphorylation of STAT3 was also diminished. One mechanism of growth factor stimulation to 
STAT3 phosphorylation is through direct c-Src activation (100). However, our initial hypothesis 
that c-Src mediates c-Met to STAT3 activation has been disproved. Treatment with the c-Src 
inhibitor, PP2, was unable to hinder activation of STAT3 at later time points (8-48 hours after 
EGF stimulation). C-Met has is capable of interacting with and activating STAT3 through its 
SH2 domain (110). Co-immunprecipitation experiments revealed associations between STAT3 
and c-Met 8-24 hours post-EGFR ligand stimulation. This suggests activated c-Met is directly 
acting upon STAT3 to induce phosphorylation and nuclear accumulation. The biological activity 
of STAT3 as a transcription factor requires cytoplasmic-nuclear translocation of STAT proteins 
(107). Free cytosolic diffusion from the plasma membrane to the nucleus is a favored model for 
this translocation. However, there has been more evidence of RTKs, including c-Met, signaling 
from endosomal compartments and not at the plasma membrane. In fact, when stimulated by 
HGF, STAT3 phosphorylation and nuclear translocation has been shown to require nuclear-
proximal activated c-Met in HeLa cells (107). In that study, sustained phosphorylation of STAT3 
was dependent on c-Met being delivered to a perinuclear endosomal compartment. It is possible 
that the delayed c-Met mode of signaling occurs through intracellular relocalization of c-Met 
molecules. These subcellular populations may then interact with different effector molecules as 
seen in the canonical pathway.  
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These downstream effectors of the delayed c-Met signaling cascade following EGF-
stimulation have yet to be discovered. In order to determine which mediators are modulated in 
response to delayed c-Met activation, whole genome microarray analysis will be completed. 
201T cells have been transiently transfected with siRNA for non-targeting (NT) or c-Met. 
Transfected cells were stimulated with EGF for 0, 24, or 48 hours, or HGF for 5 minutes. RNA 
and protein was collected to confirm c-Met was knocked down through analysis by RT-PCR or 
Western blot (Figure 16). RNA will be subjected to whole genome microarray analysis on 
Illumina Bead Chips and analyzed using BRB array software. The results will be confirmed in 
NSCLC cell lines and used as a starting point for the identification of novel targets for inhibition 
of EGFR and c-Met signaling cascades. We are particularly interested in observing differences in 
genes that are transcriptionally activated by STAT3 (MMP-2, MMP-9, integrin β6). 
 
 
 
 
Figure 17. C-Met siRNA successfully knocks down c-Met RNA and protein levels. 201T cells were 
treated with either non-targeting siRNA (NT) or c-Met siRNA for 8 hours. Cells were then serum starved 
24 hours prior to treatment with EGF (0, 24, 48 hours) or HGF (0, 5 minutes). RT-PCR for c-Met was 
performed on extracted RNA. Protein lysates were also analyzed for total c-Met. 
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4.0  DISCUSSION 
This project was focused on aspects of the HGF/c-Met signaling pathway that are relevant to 
lung cancer. Growth factor stimulation of angiogenic and invasive phenotypes is well known to 
contribute to the promotion and progression of malignancies, including NSCLC (11, 12). To this 
extent VEGF and EGFR signaling pathways have been predominantly studied in the past. 
However, several clinical trials have shown resistance to targeted VEGFR and EGFR therapies. 
Activating mutations of downstream effector molecules and compensatory signaling from 
overlapping growth factor pathways are two of the main contributors for resistance (12). The 
HGF/c-Met signaling pathway has been shown to confer resistance to both VEGFR and EGFR 
therapeutics in NSCLC (21, 51, 84, 98). This coupled with the strong correlation between HGF 
and/or c-Met expression with poor patient survival (70-72), supports the hypothesis that HGF/c-
Met pathway plays an important role in the pathogenesis of human cancers and is a potential 
target for therapeutic intervention.   
The first aspect of c-Met signaling in this study was focused on the ability of over-
expressed HGF to promote angiogenesis in normal whole lungs and lung tumors. We observed 
an increase in microvessel density in HGF TG animals compare to WT littermates that increased 
with age. Further characterizing blood vessel formation in these mice, we validated that 
endothelial cells in the HGF TG and WT mice both express the c-Met receptor. Thus, suggesting 
HGF may directly stimulate these cells to promote vessel formation. A higher percentage of 
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immature vessels (as determined by the absence of SMA) was seen in HGF TG mice compared 
to WT littermates at an intermediary age of 20 weeks. This confirms HGF over-expression 
continually stimulates blood vessel formation throughout the animal’s life. A higher percentage 
of lymphatic vessels was also observed in transgenic mice compared to WT. HGF has been 
shown to regulate lymph vessel formation (100). Increases in blood and lymph vasculature 
contribute to tumor proliferation and metastasis.    
To further understand key regulators of HGF induced angiogenesis, microarray analysis 
was completed on whole lung and tumor samples from HGF TG and WT mice. Analysis 
demonstrated an overwhelming reduction in expression of angiogenic related genes, such as the 
VEGF gene family. However, at 10 weeks of age, and in tumor samples, a few pro-angiogenic 
CXC chemokines were up-regulated greater than 2-fold in the transgenic mice. The two CXC 
chemokines with highest expression, Cxcl1 and Cxcl2, are homologues of human IL-8. 
Interleukins, specifically IL-8 and IL-6, have been revealed as pro-angiogenic cytokines in many 
cancers including NSCLC (32, 33). HGF can promote the induction of IL-8 in NPC and lung 
adenocarcinoma cells (90, 91).  
The results from studying this aspect of c-Met signaling, suggest HGF over-expression 
mainly affects continued enhancement of vascularization with down-regulation of other key 
angiogenic factors such as the VEGF genes. These results could be used to further explain 
resistance to anti-VEGF therapies, which are currently being tested in several cancers, including 
NSCLC (17, 19). Resistance to bevacizumab and sunitinib has already been linked to HGF/c-
Met expression (19, 21). Our animal model could be further used to study VEGF-independent 
angiogenesis in the hopes of identifying novel anti-angiogenic and anti-tumorigenic targets.  
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C-Met when stimulated by its ligand, HGF, initiates signaling cascades which results in a 
variety of biological effects. More recent studies have shown that c-Met may also be stimulated 
via HGF-independent mechanisms. The second aspect of c-Met signaling in this paper was 
focused on a mechanism of ligand-independent activation, EGFR crosstalk. Previous 
experiments by our laboratory revealed that EGFR could induce c-Met activation 8 hours after 
EGFR ligand stimulation (80). This activation is extended up to 48 hours post EGF treatment. 
Moreover, this delayed activation of c-Met was necessary to achieve maximal induction of 
invasion and migration by EGFR (80). The EGFR and c-Met pathways activate similar 
downstream effector molecules such as Kras/ MAPK, PI3K/AKT, and STAT. EGFR may utilize 
c-Met to amplify its signal to their shared downstream effectors.  
STAT3 is known to be activated immediately downstream of EGFR ligand stimulation, 
as well as, downstream of HGF activated c-Met. STAT3 is a transcription factor that plays key 
regulatory roles in pro-inflammatory cytokine release, and tumor cell motility, invasion and 
proliferation (107). STAT3 was identified as a potential mediator downstream of delayed c-Met 
signaling previously by our laboratory (80). In this study we confirmed STAT3 phosphorylation 
requires delayed c-Met activation. STAT3 demonstrated a biphasic model of activation when 
stimulated by EGF in NSCLC cell lines. Initial activation occurred within 5 minutes of 
stimulation and subsided by 2 hours. A second wave of activation appeared around 8 hours post 
treatment and was seen up to 48 hours. The delayed activation of STAT3 correlated with delayed 
c-Met phosphorylation seen previously (80). Inhibition of active c-Met at delayed time points 
with PHA665752 also blocked phosphorylation of STAT3 at similar time points. This confirms 
that delayed STAT3 activation requires EGFR-induced c-Met signaling.  
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Several mechanisms for growth factor activation of STAT3 have been reported. C-Src is 
one such mediator, which also demonstrates a biphasic phosphorylation pattern in response to 
EGF. However, inhibition of delayed phospho-Src by PP2 failed to impede activation of STAT3. 
Co-immunoprecipitation of c-Met and STAT3 at 8-24 hours post EGF treatment highly suggests 
c-Met directly activates STAT3. In HeLa cells, c-Met signaling from perinuclear compartments 
was required for sustained phosphorylation and nuclear translocation of STAT3 (107). It is 
possible that in NSCLC cells, c-Met when activated via EGFR signals from intracellular 
compartments, potentially interacting with and activating those molecules which play a minor 
role in canonical signaling from the plasma membrane.  
In order to better understand c-Met signaling in lung cancer, further investigation is 
essential. Improved understanding of critical intermediates involving in two differing c-Met 
signaling cascades (dependent or independent of ligand) would be useful for identifying key 
targets for NSCLC therapy. Combinational studies have highlighted the need for targeting 
multiple RTK inputs at once. In gliobastoma multiforme, a cocktail inhibitor of EGFR, c-Met, 
and PDGFR is necessary to completely block survival signaling through the PI3K/Akt pathway 
(111). Another study illustrated that dual treatment with a VEGFR/PDGFR inhibitor, sunitinib, 
and c-Met inhibitor significantly repressed tumor growth compared to sunitinib treatment alone 
(19). Our laboratory has recently shown that the combination of EGFR and c-Met TKIs has a 
greater effect on blocking pathways responsible for xenograft tumor progression compare to 
single target therapy alone (80). The redundancy of growth factor pathways can limit the efficacy 
of single agent angiogenic treatments. Thus, by further studying HGF/c-Met promotion of 
VEGF-independent angiogenesis, and EGFR-stimulated c-Met activation, we can identify ideal 
targets for inhibition of multiple pathways or combination therapy in NSCLC. 
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APPENDIX A 
TABLE 5 
Table 5. Genes with insignificant expression changes. 
  HGF WT HGF TG     
Symbol Avg Delta Ct STD Avg Delta Ct STD Fold Change p 
10 week       
 Csf3 -1.60 10.35 5.74 11.19 0.01 0.571 
 F2 1.47 9.29 8.63 0.61 0.01 0.286 
 Ereg 2.76 8.26 7.81 2.22 0.03 0.286 
 Hand2 10.17 2.88 13.28 2.10 0.12 0.272 
 Col18a1 4.36 0.38 6.98 2.62 0.16 0.101 
 Bai1 11.33 1.06 12.88 2.15 0.34 0.466 
 Timp1 12.04 0.65 13.29 2.13 0.42 0.917 
 Efnb2 -1.68 1.11 -0.45 0.82 0.43 0.117 
 Vegfa 0.19 0.44 1.37 0.82 0.44 0.073 
 Anpep 4.29 0.07 5.32 1.02 0.49 0.153 
 Plxdc1 5.57 0.31 6.58 1.04 0.50 0.241 
 S1pr1 -0.30 0.52 0.67 1.18 0.51 0.172 
 Figf -0.98 0.66 -0.03 0.85 0.52 0.142 
 Plg 9.37 0.24 10.27 4.04 0.54 0.469 
 Thbs1 -0.44 0.84 0.35 1.15 0.58 0.370 
 Vegfb 3.79 0.23 4.53 0.59 0.60 0.084 
 Tbx1 2.17 0.24 2.88 1.17 0.61 0.436 
 Nrp1 -2.31 0.82 -1.70 0.28 0.66 0.153 
 Tgfa 4.28 0.74 4.87 0.95 0.67 0.341 
 Fzd5 2.10 0.80 2.62 0.65 0.70 0.321 
 Thbs2 5.81 1.15 6.32 3.63 0.70 0.524 
 Tnfaip2 2.60 1.29 3.11 0.40 0.71 0.336 
 Jag1 2.61 0.74 3.09 0.92 0.72 0.454 
 Tek -2.10 0.76 -1.64 0.29 0.73 0.210 
 Tgfb3 4.45 0.33 4.84 0.69 0.76 0.406 
 Ctgf -1.98 0.75 -1.62 0.40 0.78 0.385 
 Tmprss6 8.87 0.42 9.21 1.08 0.79 0.878 
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Table 5 Continued…  
  HGF WT HGF TG   
Symbol Avg Delta Ct STD Avg Delta Ct STD Fold Change p 
 Serpinf1 1.74 0.57 2.00 0.28 0.84 0.373 
 Itgb3 3.76 0.18 3.98 0.75 0.86 0.881 
 Gna13 0.30 1.29 0.48 0.65 0.88 0.540 
 Efna1 1.85 0.14 1.89 0.35 0.97 0.961 
 Vegfc 1.48 1.05 1.47 0.27 1.01 0.694 
 Fgf6 9.02 0.67 8.89 1.26 1.10 0.642 
 Angpt2 1.94 0.63 1.73 0.30 1.16 0.652 
 Mdk 3.59 0.30 3.37 0.14 1.17 0.250 
 Ifng 8.15 0.51 7.91 1.40 1.18 0.445 
 Mmp19 5.31 0.44 4.83 1.33 1.40 0.487 
 Smad5 0.72 0.86 0.14 0.33 1.49 0.284 
 Itgav 2.38 1.31 1.74 0.49 1.56 0.496 
 Tgfbr1 4.60 1.59 3.94 0.26 1.58 0.630 
 Egf 7.73 1.33 6.97 1.58 1.69 0.482 
 Fgf1 0.82 0.95 0.02 0.43 1.74 0.159 
 Hif1a 0.42 1.40 -0.61 0.62 2.03 0.242 
 Fgf2 2.93 1.44 1.91 0.97 2.04 0.393 
 Tnf 7.96 0.99 6.91 0.76 2.07 0.218 
 Igf1 3.30 1.68 2.04 0.71 2.39 0.259 
 Il6 8.43 1.13 7.00 1.17 2.70 0.165 
 Hgf 2.36 1.90 0.90 0.36 2.76 0.105 
 Lep 8.37 0.71 6.88 0.88 2.80 0.133 
 Angpt1 1.85 2.10 0.30 0.23 2.93 0.099 
 Ccl2 7.30 1.05 5.50 0.75 3.48 0.067 
 Cxcl1 6.82 1.17 4.78 1.15 4.11 0.175 
 Ccl11 5.09 0.58 3.02 0.95 4.20 0.086 
 Pgf -1.34 3.67 -3.66 4.05 4.98 0.464 
 Cxcl2 6.02 1.16 3.62 1.32 5.31 0.233 
 Lect1 9.62 2.27 6.81 4.35 7.02 0.436 
 Tymp 5.04 0.56 0.06 4.22 31.63 0.367 
  Avg STD Avg STD Ratio (TG:WT) p 
 40 week             
Tnfrsf25 0.44 0.16 0.09 0.01 0.21 0.097 
Cd44 0.71 0.25 0.16 0.09 0.22 0.098 
Pik3c2a 0.41 0.18 0.09 0.02 0.22 0.132 
Fos 0.59 0.24 0.14 0.09 0.23 0.127 
Ncam1 0.47 0.23 0.11 0.03 0.24 0.163 
Fas 0.52 0.35 0.14 0.09 0.27 0.274 
Nfkb1 0.82 0.11 0.23 0.16 0.28 0.051 
Casp8 0.30 0.21 0.09 0.02 0.29 0.292 
Map2k1 0.56 0.26 0.16 0.12 0.29 0.191 
Rasa1 0.33 0.23 0.10 0.03 0.29 0.293 
S100a4 0.68 0.26 0.20 0.09 0.29 0.131 
Rb1 0.54 0.25 0.16 0.06 0.30 0.175 
Serpine1 0.90 0.04 0.28 0.26 0.31 0.077 
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Table 5 Continued…  
  HGF WT HGF TG   
Symbol Avg Delta Ct STD Avg Delta Ct STD Fold Change p 
Cd82 0.28 0.11 0.09 0.02 0.31 0.138 
Icam1 0.55 0.38 0.18 0.13 0.32 0.316 
MMP9 0.25 0.15 0.08 0.01 0.34 0.025 
Akt2 0.31 0.10 0.11 0.05 0.34 0.109 
Myc 0.22 0.12 0.08 0.01 0.34 0.227 
Jun 0.78 0.23 0.27 0.16 0.34 0.124 
Itgb1 0.27 0.19 0.09 0.04 0.35 0.331 
Ccl2 0.31 0.36 0.11 0.03 0.35 0.316 
Cdc25a 0.26 0.17 0.09 0.03 0.36 0.306 
Mdm2 0.20 0.14 0.07 0.01 0.36 0.334 
Mcam 0.79 0.17 0.30 0.20 0.38 0.121 
Hgf 0.22 0.19 0.08 0.04 0.38 0.120 
Ets2 0.20 0.14 0.08 0.01 0.38 0.346 
Gzma 0.17 0.12 0.07 0.01 0.39 0.333 
Cxcl2 0.43 0.38 0.17 0.16 0.40 0.131 
Plaur 0.21 0.07 0.08 0.02 0.40 0.125 
Raf1 0.19 0.07 0.08 0.02 0.40 0.142 
Nme4 0.21 0.06 0.09 0.02 0.41 0.102 
Egfr 0.16 0.05 0.07 0.00 0.44 0.112 
Casp9 0.51 0.26 0.22 0.17 0.44 0.323 
MMP2 0.29 0.06 0.13 0.05 0.44 0.000 
Erbb2 0.15 0.06 0.07 0.00 0.44 0.199 
Cxcl1 0.22 0.25 0.10 0.05 0.45 0.302 
Npr1 0.38 0.14 0.18 0.11 0.46 0.061 
Ephb4 0.44 0.14 0.20 0.19 0.46 0.090 
Pdgfb 0.30 0.32 0.14 0.10 0.47 0.281 
Ccnd1 0.23 0.10 0.11 0.05 0.47 0.267 
Hif1a 0.17 0.09 0.08 0.03 0.48 0.072 
Il6 0.15 0.13 0.08 0.01 0.50 0.283 
Serpinb2 0.13 0.06 0.07 0.00 0.51 0.279 
Nudt6 0.26 0.12 0.13 0.06 0.51 0.100 
Cdkn1a 0.17 0.02 0.09 0.02 0.52 0.062 
Serpinb5 0.12 0.02 0.06 0.00 0.52 0.072 
Ccl11 0.18 0.14 0.09 0.02 0.52 0.200 
Cdh1 0.12 0.08 0.06 0.00 0.52 0.417 
Cdkn1b 0.12 0.05 0.06 0.00 0.52 0.219 
Mta2 0.13 0.05 0.07 0.00 0.52 0.206 
Mta1 0.13 0.04 0.07 0.00 0.53 0.143 
Mdk 0.21 0.05 0.11 0.03 0.53 0.011 
Efna3 0.14 0.08 0.08 0.02 0.53 0.183 
Mapk14 0.89 0.10 0.48 0.35 0.54 0.021 
Met 0.12 0.05 0.07 0.00 0.56 0.240 
Prkdc 0.12 0.02 0.07 0.00 0.57 0.076 
Pten 0.11 0.05 0.07 0.01 0.57 0.053 
Notch4 0.27 0.13 0.16 0.13 0.57 0.251 
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Table 5 Continued…  
  HGF WT HGF TG   
Symbol Avg Delta Ct STD Avg Delta Ct STD Fold Change p 
Anpep 0.11 0.03 0.07 0.02 0.58 0.034 
Muc1 0.12 0.03 0.07 0.00 0.58 0.134 
Efnb2 0.75 0.11 0.44 0.33 0.59 0.125 
Cflar 0.10 0.04 0.06 0.00 0.60 0.272 
Tbx1 0.23 0.09 0.14 0.08 0.60 0.185 
Itga3 0.10 0.04 0.06 0.00 0.61 0.301 
Src 0.11 0.02 0.07 0.00 0.61 0.111 
Wasf2 0.26 0.08 0.16 0.09 0.62 0.140 
Mtss1 0.11 0.03 0.06 0.00 0.62 0.156 
Ccne1 0.10 0.04 0.06 0.00 0.62 0.286 
Twist1 0.10 0.02 0.07 0.00 0.63 0.101 
Sphk1 0.68 0.15 0.43 0.34 0.63 0.224 
Trp53 0.10 0.02 0.06 0.00 0.64 0.162 
Lep 0.12 0.05 0.08 0.01 0.64 0.139 
Ecgf1 0.16 0.04 0.10 0.06 0.64 0.162 
Ifng 0.10 0.04 0.06 0.01 0.64 0.112 
Timp2 0.42 0.21 0.27 0.23 0.65 0.382 
Prok2 0.11 0.04 0.07 0.00 0.65 0.093 
Itgb5 0.10 0.03 0.06 0.00 0.65 0.246 
Pgf 0.10 0.04 0.06 0.01 0.65 0.147 
Angpt2 0.19 0.05 0.12 0.07 0.65 0.187 
Stab2 0.10 0.04 0.07 0.01 0.65 0.164 
Tmprss6 0.10 0.04 0.06 0.01 0.66 0.121 
Il10 0.13 0.03 0.08 0.03 0.66 0.088 
Pecam1 0.12 0.05 0.08 0.01 0.67 0.171 
Epas1 0.09 0.05 0.06 0.01 0.67 0.284 
Tgfb1 0.13 0.06 0.09 0.02 0.68 0.144 
Ptn 0.36 0.30 0.25 0.10 0.68 0.489 
Cxcl10 0.09 0.03 0.07 0.01 0.69 0.161 
Cdh5 0.09 0.04 0.06 0.01 0.70 0.259 
Ctgf 0.96 0.05 0.67 0.31 0.70 0.112 
Ifna1 0.08 0.04 0.06 0.01 0.70 0.191 
Lect1 0.09 0.04 0.07 0.02 0.71 0.246 
Tnfaip2 0.10 0.02 0.07 0.02 0.72 0.066 
Fgf6 0.08 0.02 0.06 0.01 0.72 0.137 
Edg1 0.96 0.05 0.69 0.25 0.72 0.079 
Plg 0.13 0.02 0.09 0.02 0.72 0.077 
Itgb3 0.10 0.05 0.07 0.02 0.73 0.156 
Jag1 0.16 0.05 0.12 0.06 0.73 0.293 
Hand2 0.09 0.03 0.06 0.01 0.74 0.249 
Cxcl11 0.08 0.03 0.06 0.01 0.74 0.260 
Cxcl5 0.08 0.02 0.06 0.01 0.74 0.118 
TEK 0.87 0.10 0.65 0.28 0.75 0.099 
Il12a 0.95 0.05 0.72 0.35 0.76 0.241 
Smad5 0.09 0.03 0.07 0.00 0.76 0.184 
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Table 5 Continued…  
  HGF WT HGF TG   
Symbol Avg Delta Ct STD Avg Delta Ct STD Fold Change p 
Tnnt1 0.09 0.02 0.07 0.00 0.76 0.072 
Gna13 0.08 0.02 0.06 0.02 0.77 0.210 
Angptl3 0.08 0.02 0.06 0.01 0.77 0.210 
Nppb 0.08 0.01 0.06 0.01 0.78 0.105 
Tgfbr1 0.09 0.02 0.07 0.02 0.78 0.049 
Thbs1 0.09 0.02 0.07 0.02 0.78 0.096 
Timp1 0.09 0.02 0.07 0.01 0.78 0.157 
Il1b 0.76 0.31 0.59 0.15 0.78 0.382 
Ptgs1 0.95 0.05 0.75 0.21 0.79 0.109 
F2 0.07 0.02 0.06 0.01 0.79 0.277 
Bai1 0.19 0.19 0.15 0.11 0.79 0.617 
Egf 0.10 0.03 0.08 0.03 0.80 0.220 
Mmp19 0.08 0.02 0.06 0.01 0.80 0.184 
Ereg 0.07 0.02 0.05 0.02 0.80 0.266 
Tnfsf12 0.08 0.02 0.06 0.01 0.81 0.166 
Tnfsf15 0.08 0.02 0.06 0.01 0.81 0.237 
Stab1 0.07 0.02 0.06 0.01 0.81 0.284 
Lama5 0.09 0.02 0.07 0.02 0.82 0.389 
Fgfr3 0.07 0.02 0.06 0.01 0.83 0.377 
ItgaV 0.09 0.03 0.07 0.02 0.83 0.279 
Kdr 0.11 0.03 0.09 0.04 0.84 0.508 
Tbx4 0.08 0.02 0.07 0.00 0.84 0.231 
Fgf2 0.08 0.02 0.07 0.02 0.86 0.270 
Il18 0.87 0.10 0.75 0.16 0.86 0.249 
Fzd5 0.06 0.02 0.06 0.02 0.87 0.530 
Adra2b 0.20 0.07 0.18 0.08 0.87 0.617 
Sh2d2a 0.07 0.02 0.06 0.01 0.87 0.384 
Angpt1 0.08 0.02 0.07 0.02 0.90 0.503 
Tgfb2 0.08 0.02 0.07 0.01 0.92 0.587 
Serpinf1 0.08 0.02 0.08 0.02 0.94 0.774 
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